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ABSTRACT 
 
BACKGROUND:. The clinical relevance of isolated non-ischemic left-ventricular (LV) scar as a cause of 
ventricular arrhythmias and sudden death in the young and athlete remains to be established. 
Contrast-enhanced cardiac magnetic resonance (CE-CMR) is increasingly used in the clinical work-up 
of athletes with apparently idiopathic ventricular arrhythmias (VA) and can reveal LV scar in the form 
of late gadolinium enhancement (LGE). 
AIMS: we aimed to: 1) evaluate the incidence and causes (with particular reference to non-ischemic 
LV scar) of out-of-hospital cardiac arrest (OHCA) in people 1-40 year-old in the Padua province in the 
modern era; 2) assess the clinical profile and outcome of athletes referred to our Institution for non-
ischemic LV scar as suggested by LGE at CE-CMR, which was performed for evaluation of apparently 
idiopathic VA and/or ECG abnormalities; 3) evaluate whether a strategy consisting of 24-hours 12-
leads ambulatory ECG monitoring as first-line investigation and CE-CMR as second line investigation 
may improve our ability to identify concealed LV scar in apparently healthy athletes. 
METHODS: we performed three different studies: 1) we recorded all cases of OHCA which occurred 
during the period 2011-2015. The study population included all residents in the province of Padua 1-
40 year-old who suffered OHCA, either resuscitated or not, of presumed cardiovascular origin. The 
cause of OHCA was ascertained clinically in survivors and at postmortem investigation in victims of 
sudden death; 2) we compared the clinical profile and outcome of 35 athletes with VA and isolated 
non-ischemic (subepicardial/midmyocardial) LGE on CE-CMR suggesting myocardial scar with 38 
athletes with VA and no LGE and 40 healthy control athletes; 3) we offered a 12-leads 24-hours 
ambulatory ECG monitoring to apparently healthy athletes ≥16 year-old, who performed at least 6 
hours of physical exercise per week and who have been considered eligible at preparticipation 
screening within 1 year. Athletes were selected to undergo CE-CMR if they showed >29 premature 
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ventricular beats (PVBs) of “uncommon morphology” (i.e. excluding those with a morphology 
suggestive of right ventricular outflow tract or fascicular origin) or repetitive VA (excluding isolated 
couplets with a morphology suggestive of right ventricular outflow tract origin). 
RESULTS: the main results for each study were: 1) the incidence of OHCA in the Padua province was 
3.5/100.000 residents/year and was significantly lower among screened athletes than among non-
athletes (1.1/100.000/year vs. 3.9/100.000/year, p<0,001). A final diagnosis was reached in 40 (83%) 
subjects while in 8 (17%) victims of sudden death the autopsy was not performed. The most frequent 
diagnosis were coronary artery atherosclerosis (23%) and structurally normal heart (23%) while 
cardiomyopathies accounted for 10% of cases. The most frequent cardiomyopathy (3 of 7 cases) was 
the non-ischemic LV scar; 2) a “stria” LGE pattern with subepicardial/midmyocardial distribution, 
mostly involving the lateral LV wall, was found in 27 (77%) of athletes with VA versus 0 controls 
(p<0.001). All athletes with “stria” LGE pattern showed VA with a predominant right-bundle-branch-
block morphology (suggesting LV origin) but only 5/27 (19%) showed hypokinesis of the lateral LV 
wall at echocardiography. During a follow-up of 38±25 months, 6/27 (22%) athletes with a “stria” LGE 
pattern experienced major arrhythmic events (including 1 sudden death) compared with none of 
athletes with no or LGE-“spotty” pattern; 3) PVBs were rare in apparently healthy athletes (median 
1/day) and their number and complexity significantly correlated with age. The prevalence of frequent 
or repetitive PVBs with “uncommon” morphology was 28/384 (7.3%) apparently healthy. athletes. In 
this group, 3/28 (11%) showed non-ischemic LV scar at CE-CMR. 
CONCLUSIONS: the non-ischemic LV scar with a “stria” pattern may be associated with life-
threatening VA and sudden death in the young athlete and cannot be simply dismissed as a sign of a 
previous healed myocarditis. Because of its subepicardial/midmyocardial location, the LV scar is 
often undetectable by echocardiography, and athletes with PVBs with right-bundle-branch-block 
morphology, particularly if exercise-induced or associated with ECG abnormalities, should undergo 
CE-CMR to exclude an underlying pathological myocardial substrate. 
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Abbreviations list 
1.ARVC=arrhythmogenic right ventricular cardiomyopathy 
2.CE-CMR=contrast-enhanced cardiac magnetic resonance 
3.HCM=hypertrophic cardiomyopathy 
4.LBBB=left bundle branch block 
5.LGE=late gadolinium enhancement 
6.LV=left ventricle 
7.OHCA=out-of-hospital cardiac arrest 
8.PVBs=premature ventricular beats 
9.RBBB=right bundle branch block 
10.SD=sudden death 
11.VA=ventricular arrhythmias 
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INTRODUCTION 
The issue of sudden death in the athletes 
Incidence 
 The risk of sudden death (SD) among athletes or during sports activity varies in the different 
series reported in the literature1-27. It generally increases with age and is greater in men. In 
apparently healthy adults (>35 years), joggers or marathon racers, the estimated rate of SD ranges 
from 1:15,000 to 1:50,000/year. In comparison, a significantly lower incidence of fatal events have 
been reported in young athletes (≤35 years), in the range of 0.5-1/100,000/year (Table 1). Van Camp 
et al. in a nationally based survey estimated the prevalence of SD in high school and college athletes 
in the United States to be 0.4 per 100,000 athletes per year between 1983 and 199328. Maron et al. 
found a prevalence of SD in high school athletes from Minnesota (age 12 to 19 years, mean 16) over 
a 26-years study period of 0.7/100.000/year23. In contrast, Harmon et al. reported a higher 
(2.28/100.000/year) incidence of SD among athletes of the National Collegiate Athletic Association 14. 
A prospective study in the Veneto Region of Italy reported an incidence of SD of 2.3 (2.62 in males 
and 1.07 in females) per 100.000 athletes per year from all causes, and of 2.1 per 100.000 athletes 
per year from cardiovascular diseases1. The different SD rate found in different studies may be 
explained by a variety of factors, including the age range, the proportion of men, the estimation of 
the denominator and the methodology of data collection (prospective collection vs. retrospective 
analysis of data from public media reports and insurance claims). To this regard Harmon et al. found 
that only 56% of SD cases would have been identified relying on media reports (including internet) 
only14. The risk of SD in athletes increases with age and is greater in men (Table 1). A recent French 
study reported an incidence of SD during moderate or vigorous exercise of 1/100.000/year among 
males and of 0.05/100.000/year among females29. 
  
Table 1. Main studies reporting the incidence of cardiac arrest/sudden death in the young and/or during sports activity.  
Ref. Study period Region Population Results 
Maron, 
JACC 1998 
1985/1986-
1996/1997 Minnesota, USA 
651.695 High School athletes  
13-19 year-old 
SD among athletes during competition or training: 
0.46/100.000/yr. 
Corrado, 
JACC 2003 1979-1999 Veneto, Italia 
1.386.600 people 12-35 year-old 
112.970 athletes 12-35 year-old 
SD in the general population: 0.9/100.000/yr. 
SD among athletes: 2.3/100.000/yr. 
Gerein,  
AEM 2006 1991-2002 Ontario, Canada 
500.000 people 
0-18 year-old OHCA: 9.1/100.000/yr. 
Corrado, 
JAMA 2006 1979-2004 Veneto, Italia 
2.938.730 athletes 12-35 year-old 
33.205.370 non athletes 12-35 
year-old 
Cardiovascular SD among athletes: 1.9/100.000/yr. 
Cardiovascular SD among non-athletes: 0.79/100.000/yr. 
SD rate reduction after screening implementation: 89% 
Ong, 
Resuscitation 2006 1992-2002 Ontario, Canada 
800.000 people 
0-19 year-old OHCA: 5.97/100.000/yr. 
Maron, 
Circulation 2009 2001-2006 USA 
10.700.000 athletes  
13-25 year-old Cardiovascular SD among athletes: 0.61/100.000/yr. 
Chugh, 
Heart Rhythm 2009 2002-2005 
Multnomah County, 
Oregon, USA 
Estimated number of children 
0-14 year-old 
SD rate 1-13 year-old : 7.5/100.000/yr. 
SD rate <1 yr.: 96.0/100.000/yr. 
Atkins, 
Circulation 2009 2005-2007 Canada 
Canadian population 
0-19 year-old 
OHCA rate <1 yr.: 72.71/100.000/yr. 
OHCA rate 1-11 year-old: 3.73/100.000/yr. 
OHCA rate 12-19 year-old: 6.73/100.000/yr. 
OHCA rate 0-19 year-old: 8.04/100.000/yr. 
Solberg, 
Eur J Prev. Cardiol 2010 1990-1997 Norway 
Norwegian population 
15-34 year-old Sports-related SD: 0.9/100.000/yr. 
Holst, 
Heart Rhythm 2010 2000-2006 Denmark 
Danish population 
12-35 year-old 
Sports-related SD: 1.21/100.000/yr. 
SD in the general population: 3.76/100.000/yr. 
Donohoe, 
Resuscitation 2010 2003-2007 London, UK 
4.000.000 people 
0-35 year-old 
OHCA rate 0-35 year-old: 19.3/100.000/yr. 
OHCA rate in the general population: 131.2/100.000/yr. 
Park, 
Resuscitation 2010 2006-2007 South Korea 
South Korean population 
0-20 year-old 
OHCA rate <1 yr.: 67.1/100.000/yr. 
OHCA rate 1-11 year-old : 2.5/100.000/yr. 
OHCA rate 12-20 year-old: 3.5/100.000/yr. 
OHCA rate 0-20 year-old: 4.2/100.000/yr. 
  
 
Deasy, 
Resuscitation 2010 1999-2007 Melbourne, Australia 
810.400 people 
0-16 year-old OHCA rate: 3/100.000/yr. 
Harmon, 
Circulation 2011 2004-2008 USA 
1.969.663 athletes/year 
17-23 year-old Cardiovascular SD among athletes: 2.28/100.000/yr. 
Winkel, 
Eur Heart J 2011 2000-2006 Denmark 
2.380.000 people 
1-35year-old Cardiovascular SD rate: 2.8/100.000/yr. 
Margey, 
Europace 2011 2005-2007 Ireland 
Irish population 
15-35 year-old Cardiovascular SD rate: 2.85/100.000/yr. 
Eckart, 
JACC 2011 1998-2008 
US Military training 
base US Military recruits 
SD rate <20 year-old: 3.3/100.000/yr. 
SD rate >50 year-old: 106/100.000/yr. 
Meyer, 
Circulation 2012 1980-2009 
King County, 
Washington 
620.000 people 
0-35 year-old 
Overall OHCA rate : 2.28/100.000/yr. 
OHCA rate 0-2 year-old: 2.1/100.000/yr. 
OHCA rate 3-13 year-old: 0.61/100.000/yr. 
OHCA rate 14-24 year-old: 1.44/100.000/yr. 
OHCA rate 25-35 year-old: 4.40/100.000/yr. 
Roberts, 
JACC 2013 
1993/1994-
2011/2012 Minnesota, USA 1.666.509 High School athletes Cardiovascular SD among athletes: 0.24/100.000/yr. 
Pilmer, 
Heart Rhythm 2013 2008 Ontario, Canada 
6.602.680 people 
2-40 year-old 
Cardiovascular SD rate 2-18 year-old: 0.7/100.000/yr. 
Cardiovascular SD rate 19-29 year-old: 2.4/100.000/yr. 
Cardiovascular SD rate 30-40 year-old: 5.3/100.000/yr. 
Berdowsky, 
Eur Heart J 2013 2006-2008 North Holland 
2.400.000 people 
10-90 year-old 
1.000.000 people 
10-35 year-old 
Exercise related OHCA during the study period: 5.7%  
Exercise related OHCA rate 10-90 year-old: 2.1/100.000/yr. 
Exercise related OHCA rate 10-35 year-old: 0.3/100.000/yr. 
At rest OHCA rate 10-90 year-old: 35.5/100.000/yr. 
At rest OHCA rate 10-35 year-old: 2.8/100.000/yr. 
Maron, 
Heart Rhythm 2013 1986-2011 Minnesota, USA 1.930.504 High school athletes  SD rate among athletes: 0.7/100.000/yr. 
Risgaard, 
Circulation 2014 2007-2009 Denmark 
3.470.000 people 
1-49 year-old 
Overall cardiovascular SD rate: 8.6/100.000/yr. 
Cardiovascular SD rate: 31-49 year-old: 21.7/100.000/yr. 
Cardiovascular SD rate: 1-35 year-old: 2.3/100.000/yr. 
Pilmer, 
Heart Rhythm 2014 2005-2009 Ontario, Canada 
14.893.860 people 
1-19 year-old 
Cardiovascular SD rate 1-2 year-old: 3.1/100.000/yr. 
Cardiovascular SD rate 2-4 year-old: 1.3/100.000/yr. 
Cardiovascular SD rate 5-9 year-old: 0.4/100.000/yr. 
Cardiovascular SD rate 10-14 year-old: 0.5/100.000/yr. 
Cardiovascular SD rate 15-19 year-old: 1.0/100.000/yr. 
  
OHCA= out-of-hospital cardiac arrest, SD= sudden death 
,
Harmon, 
Circulation 2015 2003-2013 
USA  National Collegiate Athletic Association 17-24 year-old 
SD in the athletes: 1.9/100.000/yr 
SD in male athletes: 2.6/100.000/yr 
SD in female athletes: 0.8/100.000/yr 
SD in black athletes: 4.7/100.000/yr 
SD in white athletes: 1.5/100.000/yr 
Marijon, 
Circulation 2015  2002-2013 Portland Oregon, USA 
679.348 people 
35-65 year-old 
Exercise-related OHCA: 2.2/100.000/yr (5% total) 
Relative risk in men vs. women = 18.7 
Bohm, 
Eur J Prev Cardiol 2016 2012-2014 Germany 
Exercise-related SD 
10-79 year-old 
SD in sports participants ≥18 year-old = 0.12/100.000/yr 
SD in male: 0.16/100.000/yr 
SD in female: 0.006/100.000/yr 
Grani, 
Eur J Prev Cardiol 2016 1999-2010 Switzerland 
Exercise-related SD 
10-39 year-old 
Competitive athletes: 0.9/100.000/yr 
Recreational athletes: 0.5/100.000/y 
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The striking male predominance (male to female ratio up to 10:1) of SD in athletes has been related 
to the higher participation rate of male compared with female in competitive sports, the more 
intensive training load and level of athletic achievement of males, and the greater prevalence and/or 
phenotypic expression in young males of cardiac diseases at risk of arrhythmic cardiac arrest, such as 
cardiomyopathies and premature coronary artery disease. 
 
Causes 
 Atherosclerotic coronary artery disease accounts for the vast majority of fatalities in older 
athletes (>35 years), while the most common causes of SD in younger athletes are genetic or 
congenital cardiovascular diseases, including cardiomyopathies and coronary artery anomalies (Table 
2). Hypertrophic cardiomyopathy (HCM) has been reported to account for more than one third of 
fatal cases in the USA 28, 30, and arrhythmogenic right ventricular cardiomyopathy (ARVC) for 
approximately one fourth of cases in the Veneto Region of Italy 1, 3, 31. A sizeable proportion of young 
people and athletes who die suddenly have no evidence of structural heart disease and the cause of 
their cardiac arrest in all likelihood is related to a primary electrical heart disease such as inherited 
cardiac ion channel defects (channelopathies), including long and short QT syndromes, Brugada 
syndrome and catecholaminergic polymorphic ventricular tachycardia 32. Sudden death may also be 
caused by a non-arrhythmic mechanism-e.g., spontaneous aortic rupture complicating Marfan’s 
syndrome or bicuspid aortic valve, as well as by diseases not related to the heart—e.g., bronchial 
asthma or rupture of a cerebral aneurysm. Blunt, non-penetrating and often innocently appearing 
blows to the precordium may trigger ventricular fibrillation without structural injury to ribs, sternum, 
or heart itself (commotio cordis)33. 
The risk-benefit ratio of physical exercise differs between adults and young competitive 
athletes because of the different nature of cardiovascular causes of death. Several epidemiologic 
studies have assessed the relationship between physical exercise and the risk of acute myocardial 
infarction/SD in the middle-aged/senior individuals engaged in leisure sports activity, in which 
  
 
Table 2. Main studies reporting the cause of cardiac arrest/sudden death in the young and/or during sports activity. 
Ref Study period Region Population Causes (shown if ≥5%) 
Corrado, 
JACC 2003 1979-1999 Veneto, Italy 
1.386.600 people 12-35 year-old 
112.970 athletes 12-35 year-old 
Cardiovascular SD: 86% 
CAD: 22% 
ARVC: 14% 
Myocarditis: 12% 
Mitral valve prolapse: 10% 
Conduction system disease: 10% 
HCM: 9% 
Aortic rupture: 5% 
Non cardiovascular SD: 14% 
Unexplained SD: 8% 
Eckart, 
JACC 2004 1977-2001 US military training base US military recruits 
Cardiovascular SD: 
Coronary anomalies: 33% 
Myocarditis: 20% 
CAD: 16% 
HCM: 13% 
Puranik, 
Heart Rhythm, 2005 1995-2004 East Sidney, Australia 2.500.000 people 5-35 year-old 
Cardiovascular SD: 56% 
Structurally normal heart: 29% 
CAD: 25% 
Myocarditis: 12% 
HCM: 6% 
Aortic dissection: 5% 
Corrado, 
JAMA 2006 1979-2004 Veneto, Italia 
2.938.730 athletes 
12-35 year-old 
33.205.370 non athletes 
12-35 year-old 
Structural cardiovascular SD among athletes: 
Cardiomyopathy: 25% 
CAD: 20% 
Coronary anomalies: 13% 
Myocarditis: 13% 
Mitral valve prolapse: 11% 
Conduction system disease: 7% 
Structural cardiovascular SD among non athletes: 
Cardiomyopathy: 31% 
CAD: 20% 
Myocarditis: 15% 
Conduction system disease: 9% 
  
Mitral valve prolapse: 7% 
Coronary anomalies: 5% 
Ong, 
Resuscitation 2006 1992-2002 Ontario, Canada 800.000 people 0-19 year-old 
Cardiovascular cardiac arrest: 19% 
Of those: 
Structurally normal heart: 7% 
Maron, 
Circulation, 2009 2001-2006 USA 
10.700.000 athletes  
13-25 year-old 
Cardiovascular SD: 
Unexplained: 34% 
HCM: 24% 
Coronary anomalies: 11% 
Possible HCM: 5% 
De Noronha, 
Heart, 2009 1996-2008 United Kingdom Athletes who died suddenly 
Cardiovascular SD: 
Structurally normal heart: 23% 
Idiopatic LV hypertrophy: 31% 
ARVC: 14% 
HCM: 11% 
Idiopatic LV fibrosis: 6% 
Coronary anomalies: 5% 
Park, 
Resuscitation, 2010 2006-2007 South Korea 
South Korean population 
0-20 year-old Cardiovascular cardiac arrest: 31% 
Winkel, 
Eur Heart J 2011 2000-2006 Denmark 
2.380.000 people 
1-35 year-old 
Cardiovascular SD: 
Unexplained: 43% 
CAD: 13% 
Myocarditis: 7% 
Aortic dissection: 7% 
HCM: 6% 
Idiopatic LV fibrosis: 6% 
ARVC: 5% 
Eckart, 
JACC 2011 1998-2008 US military training base US military recruits 
Cardiovascular SD <35 year-old: 
Unexplained: 41% 
CAD: 23% 
HCM: 13% 
Myocarditis: 6% 
Dilated cardiomyopathy: 5% 
Cardiovascular SD>35 year-old: 
Unexplained: 11% 
CAD: 73% 
  
Margey, 
Eur Heart J 2011 2005-2007 Ireland Irish population 15-35 year-old 
Cardiovascular SD: 
Structurally normal heart: 26% 
CAD: 20% 
HCM: 14% 
Congenital heart diease: 9% 
LV hypertrophy: 10% 
Myocarditis: 6% 
Meyer 
Circulation, 2012 1980-2009 King County, Washington 620.000 people 0-35 year-old 
Cardiac arrest of cardiovascular origin 0-35 year-old 
Primary arrhythmia: 22% 
Cardiomyopathy: 19% 
CAD: 29% 
Congenital heart disease: 15% 
Cardiac arrest of cardiovascular origin 0-2 year-old: 
Congenital heart disease: 84% 
Primary arrhythmia: 8% 
Cardiac arrest of cardiovascular origin 3-13 year-old: 
Congenital heart disease: 21% 
HCM: 18% 
Long QT syndrome: 14% 
Primary arrhythmia: 11% 
Myocarditis: 11% 
Mitral valve prolapse: 7% 
Cardiac arrest of cardiovascular origin 14-24 year-old: 
Congenital heart disease: 23% 
Structurally normal heart: 23% 
Dilated cardiomyopaty: 14% 
Long QT syndrome: 8% 
Cardiac arrest of cardiovascular origin 25-35 year-old: 
CAD: 43% 
Structurally normal heart: 14% 
Dilated cardiomyopathy: 11% 
Pilmer, 
Heart Rhythm, 2013 2008 Ontario, Canada 6.602.680 people 2-40 year-old 
Non-ischemic cardiovascular SD: 
CMD: 35% 
HCM:17% 
Myocarditis: 13% 
Aortic dissection: 13% 
  
Cardiac tamponade: 7% 
Suarez-Mier, 
Forensic Sc Int 2013 1995-2010 Spain SD victims who underwent autopsy 
Cardiovascular SD: 
CAD: 51% 
Unexplained: 11% 
ARVC: 8% 
HCM: 7% 
Risgaard, 
Circulation 2014 2007-2009 Denmark 
3.470.000 people 
1-49 year-old 
Cardiovascular SD: 
CAD: 36% 
Unexplained: 31% 
LV hypertrophy: 8% 
ARVC: 5% 
Pilmer, 
Heart Rhythm 2014 2005-2009 Ontario, Canada 
14.893.860 people 
1-19 year-old 
Cardiovascular SD: 
Myocarditis: 25% 
ARVC: 16% 
HCM: 14% 
Possible ARVC: 9% 
Other myocardial disease: 16% 
Mitany, 
Circulation J 2014 2005-2009 Japan 
Japanese children 
6-12 year-old 
Cardiac arrest of cardiovascular origin: 
Congenital heart disease: 17% 
Primary arrhythmia: 17% 
Long QT syndrome: 16% 
HCM: 14% 
Coronary anomalies: 12% 
WPW, CPVT: 7% 
Myocarditis: 5% 
Dilated cardiomyopathy: 5% 
Young, 
Pediatrics 2014 1994-1997 
Los Angeles e Orange 
County, California, US 
US Children 
 < 12 year-old 
Cardiac arrest of cardiovascular origin: 8%  
Congenital heart disease: 5.5% 
Harmon, 
Circulation AE 2014 2004-2008 US  
National Collegiate Athletic 
Association 17-24 year-old 
Cardiovascular SD: 
Unexplained 31% 
Coronary anomalies 14% 
Idiopatic LV hypetrophy: 8% 
Aortic dissection: 8% 
Myocarditis: 8% 
Dilated cardiomyopathy: 8%  
CAD: 5% 
  
Bohm, 
Eur J Prev Cardiol 2016 2012-2014 Germany 10-79 year-old sports-related SD 
Cardiovascular SD: 85% 
Unexplained: 38% 
CAD: 29% 
Considered CAD: 15% 
Myocarditis: 8% 
Non cardiovascular SD: 15% 
Finocchiaro, 
J Am Coll Cardiol 2016 1994-2014 United Kingkdom 
Athletes victims of SD referred to 
St. George’s University of London 
Cardiac Pathology dpt. 
Unexplained: 42% 
Idiopathic LV hypertrophy/fibrosis: 16%  
ARVC: 13% 
HCM: 6% 
Myocarditis: 5% 
Grani, 
Eur J Prev Cardiol 2016 1999-2010 Switzerland 
Exercise-related SD 
10-39 year-old 
CAD: 28% 
HCM: 14% 
Unexplained: 13% 
Valvular: 8% 
Coronary anomalies: 7% 
ARVC: 7% 
Idiopathic myocardial fibrosis: 7% 
Aortic dissection: 7% 
Dilated cardiomyopathy: 6% 
ARVC= arrhythmogenic right ventricular cardiomyopathy, CAD=coronary artery disease; HCM=hypertrophic cardiomyopathy; LV=left ventricular; SD=sudden 
death; WPW=Wolff-Parkinson-White syndrome 
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exercise can be regarded as a “double-edged sword” 34-35. The available evidence indicates that 
vigorous exercise acutely increases the incidence of both cardiac arrest and acute myocardial 
infarction in those who do not exercise regularly. In comparison, epidemiologic studies support the 
concept that habitual sports activity may offer protection against cardiovascular events over the 
long-term 36-38. Adolescent and young adults involved in competitive sports activity have an 
estimated risk of SD approximately three times greater than that of their nonathletic counterpart 1, 3 
(Fig.1). Sport acts as a trigger of arrhythmic cardiac arrest in those athletes with predisposing 
cardiovascular conditions.  
 
 
Strategies for prevention of sudden death 
The catastrophic nature of SD during sports activity mandates the medical community to 
develop and implement effective preventive strategies 36, 39-41. Preparticipation screening offers the 
potential to identify asymptomatic and apparently healthy athletes who have life-threatening 
Figure 1 - Incidence and relative risk (RR) of sudden death among young athletes and non-
athletes from total, cardiovascular and non-cardiovascular causes.  
Adapted from Corrado et al. Herz 2006;31:553-8. 
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cardiovascular abnormalities and to reduce the risk of SD during sports 42-44. However, there is a 
significant debate among cardiologists about the efficacy, impact of false positive results and cost-
effectiveness of preparticipation screening 45-46. 
 
Primary prevention 
 The primary purpose of preparticipation screening is to identify the cohort of athletes 
affected by unsuspected cardiovascular diseases and to prevent SD occurring during sports by 
appropriate interventions 42-44. Many victims of SD did not experience symptoms before the event 
and, thus, pre-participation screening represents the only strategy capable of identifying the 
underlying cardiovascular disorder. The importance of early identification of clinically silent 
cardiovascular diseases at a pre-symptomatic stage relies on the concrete possibility of SD 
prevention by lifestyle modification, including restriction of competitive sports activity (if necessary), 
by prophylactic treatment with drugs and implantable defibrillator 44. 
Both the American Heart Association and the European Society of Cardiology consensus 
panel recommendations agree that cardiovascular screening for young competitive athletes is 
justifiable and compelling on ethical, legal, and medical grounds 47-48. However, there is a 
considerable discordance in the consensus guidelines on the pre-participation screening protocols 
used between European and US cardiologists/sports medicine physicians.  
The American Heart Association recommends preparticipation cardiovascular evaluation by 
means of history (personal and family history) and physical examination alone, although this 
screening protocol has a recognized limited power to detect potentially lethal cardiovascular 
abnormalities 48-49. Glover and Maron found that of 134 high school and collegiate athletes who 
suffered from SD after they underwent preparticipation screening, only 3% were suspected of having 
cardiac disease and, eventually, less than 1% received an accurate diagnosis 50. Twelve-lead ECG 
enhances the sensitivity of the screening process by allowing early detection of cardiovascular 
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conditions distinctively manifesting with ECG abnormalities, such as cardiomyopathies, pre-excitation 
syndromes and cardiac ion channel disorders 44, 47. Modern criteria for interpretation of the athletes 
ECG have led to a significant improvement in the accuracy of the ECG-based preparticipation 
screening51 (Fig.2). 
 
 
Figure 2. modern classification of ECG abnormalities in the athlete.  
The main changes compared with the 2010 European Society of Cardiology guidelines are 
underlined in red. Adapted from Zorzi et al., J Electrocardiology 2015; 48:283-291 
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In Italy the law mandates that every subject engaged in competitive sports activity must 
undergo a clinical evaluation to obtain eligibility. A nationwide mass preparticipation screening 
program, essentially based on ECG has been in practice since 1982 (Fig.3).  
 
 
The efficacy of ECG screening in the identification of cardiomyopathies has been 
demonstrated in a large population-based prospective study in the Veneto region of Italy 1, 52. Among 
33,735 athletes undergoing ECG screening at the Center for Sports Medicine in Padua, 22 (0.07%) 
were identified with HCM, based predominantly on an abnormal ECG 52. An absolute value of ECG 
screening sensitivity for HCM cannot be derived from this study because systematic 
Figure 3. Flow chart of the Italian protocol of preparticipation screening. 
First line examination includes family history, physical examination and 12-lead ECG; additional 
tests are requested only for subjects who have positive findings at the initial evaluation. The 
screening starts at the beginning of competitive athletic activity, which for the majority of sports 
disciplines corresponds to an age of 12–14 years. Athletes recognized to be affected by 
cardiovascular conditions potentially responsible for sudden death in association with exercise 
and sport participation are managed according to the available recommendations for sports 
eligibility. EPS=electrophysiologic study with programmed ventricular stimulation; MRI= magnetic 
resonance. Adapted from Corrado et al. Eur Heart J 2005;26:516-24. 
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echocardiographic findings were not available; however, this 0.07% prevalence of HCM is similar to 
that (0.10%) observed in a population-based study in the USA, using echocardiography53.  
A recent meta-analysis by Harmon et al.49 aimed to evaluated the sensitivity and specificity of 
ECG for pre-participation screening compared with history and physical examination. The study 
found that the sensitivity of ECG (80%) was superior than history (50%) and physical examination 
(33%) and that the false positive rates of history (8%) and physical examination (10%) were higher 
than that of ECG (6%). 
An Italian study provided the most compelling evidence of the efficacy of ECG screening to 
save lives by identifying and disqualifying athletes with at-risk heart diseases. A time-trend analysis of 
the incidence of SD in young competitive athletes in the Veneto region of Italy over 26 years (1979 to 
2004) showed a sharp decline of mortality rates after the introduction of the nationwide screening 
program1. Fifty-five SDs occurred in screened athletes (1.9 deaths per 100,000 person-years) and 265 
deaths in unscreened nonathletes (0.79 deaths per 100,000 person-years). The annual incidence of 
SD in athletes decreased by 89%, from 3.6 per 100,000 person-years in the pre-screening period to 
0.4 per 100,000 person-years in the late-screening period (Fig.4). 
These data have generated a number of concerns54-56. The main criticism is that the study 
was not a randomized trial comparing screening versus non-screening of young competitive athletes 
and, thus, definitive conclusions that the reduced mortality was solely the consequence of the 
screening process could not be drawn. However, the strong cause-effect relationship between ECG 
screening and the substantial reduction of SD in this prospective, population-based investigation is 
supported by the following findings: 1) there was a coincident timing between decline of SD in young 
competitive athletes and screening implementation in Italy; 2) most of the reduced incidence of SD 
was due to fewer deaths from cardiomyopathies (HCM and ARVC), and it was accompanied by the 
INTRODUCTION 
26 
 
concomitant increase of the proportion of 
these cardiomyopathies and disqualified from competition at the Center for Sports Medicine in 
Padua during the same time interval; and 3) during the study period,
change among the unscreened nonathletic population of the Veneto region of the same age range. 
Although additional factors - environmental, socio
contributed to mortality reduction over t
similarly in screened athletes and unscreened nonathletes, and hence are unlikely to explain the 
declining trend in SD selectively recorded in the screened athletic population
It has been reported that during the time interval 1993 to 2004 the 
screened Italian athletes was roughly similar 
competitors, i.e., 0.87 vs. 0.93 per 100,000 athlete
that SD in young competitive athletes is a low event
influenced by pre-participation ECG screen
Figure 4. Annual incidence rates of SD per 100,000 person, among screened competitive athletes and 
unscreened nonathletes 12-35 years of age in the Veneto Region of Italy, from 1979 to 2004. 
During the study period (the nationwide preparticipation screening program was initiated in 1982), the 
annual incidence of SD declined by 89% in screened athletes (P for trend <0.001). 
incidence of SD did not demonstrate consistent changes over that time in unscreened nonathletes. 
Modified form Corrado et al. JAMA 2006;296:1593
young competitive athletes who were identified with 
 the incidence of SD did not 
-economic or medical/surgical 
he time, such factors are expected to impact mortality 
1, 57.  
annual 
to that of unscreened US high school and college 
-years, respectively30. Thus, it has been argued 
-rate phenomenon which is unlikely to be 
ing. However, as discussed above, the two athletic 
In contrast, the 
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populations were clearly non comparable with regard to age and gender, the Italian athletes being 
much older and including more males. Moreover, the US mortality rates were unavoidably 
underestimated because of the lack of a reliable reporting system and the retrospective data 
collection mostly based on reviews of public media reports and insurance claims. On the contrary, 
the SD database in the Veneto region of Italy is unique, in so far as cases are collected according to a 
prospective study design with systematic investigation of all young people (≤35 years) who die 
suddenly and undergo a standardized investigation of the heart by a team of cardiovascular 
pathologists. The heart specimens, as well as the clinical records of all SD victims since 1979, are 
stored at the Registry of Cardiovascular Pathology, University of Padua, allowing retrieval and review 
of each case. This accounts for the greater reliability of data on causes and trends of SD in Italian 
young people and athletes, compared with reports from other countries, which are based on a less 
rigorous data collection.  
 Authors from Israel reported an incidence of SD in the athletes of 2.6/100.000/years but 
failed to demonstrated a decline in SD rate after preparticipation screening became mandatory by 
Law in 1997 in their country58. However, the study again used media reports as the sole source of 
data and this may have led to an underestimation of the true incidence of arrhythmic death among 
athletes in Israel14, 59-60. 
 
Secondary prevention 
The screening ability to detect young competitive athletes with either premature coronary 
atherosclerosis or congenital coronary anomalies is limited by the scarcity of baseline ECG signs of 
myocardial ischemia44, 47, 61. Moreover, SD during sports may be the result of non-penetrating chest 
injury (commotio cordis) which cannot be prevented by screening33. This justifies the growing efforts 
to implement additional prevention strategy based on early external defibrillation of sudden cardiac 
arrest 33. The presence of a free-standing automated external defibrillator (AED) at sporting events 
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may be a valuable intervention for conditions unrecognized by screening. However, AED should not 
be considered as a substitute of preparticipation evaluation. On-field cardiopulmonary resuscitation 
may be unsuccessful even if manoeuvres are started immediately and defibrillation equipment is 
readily available. Drezner et al. reported a 90% mortality rate from athletic-field cardiac arrest due to 
underlying cardiomyopathy, despite a witnessed collapse, timely cardiopulmonary resuscitation, and 
prompt defibrillation62. A subsequent report from the same authors on a cohort of 1,710 US high 
schools with free-standing AED program demonstrated an improved survival rate (64%) for young 
athletes with sudden cardiac arrest if early defibrillation is achieved63. Compared with previous 
studies, this higher survival rate reported in high school athletes may be explained by the higher 
proportion of sudden cardiac arrest victims treated with AED and the smaller proportion of victims 
with HCM. 
 
The non-ischemic left ventricular scar as a cause of SD in the athletes 
 An underlying structural cardiac abnormality is found at autopsy in most cases of SD during 
sports1, 3, 26, 31, 64-65. Failure to detect structural heart abnormalities before the fatal event occurs may 
depend on the low sensitivity of the current preparticipation screening protocol (based on ECG as a 
first level examination and on echocardiography as a second level examination) for subtle structural 
heart conditions potentially at risk of arrhythmic events including focal myocarditis and segmental 
cardiomyopathies 32, 66. 
 Contrast-enhanced cardiac magnetic resonance (CE-CMR) imaging has become in the recent 
years part of clinical work-up of athletes with ventricular arrhythmias (VA)67. Besides evaluating the 
presence of morpho-functional ventricular abnormalities, CE-CMR allows myocardial tissue 
characterization by late gadolinium enhancement (LGE) technique, which provides information on 
the presence, morphology and wall distribution of pathological scar tissue otherwise overlooked68-69. 
A non-ischemic left ventricular (LV) LGE suggesting myocardial scar, characteristically localized at the 
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midmyocardial and/or subepicardial layers of the LV wall, can be revealed by CE-CMR in a broad 
spectrum of heart muscle diseases at risk of SD including myocarditis, sarcoidosis, dilated 
cardiomyopathy, HCM and ARVC 70.  
 Idiopathic myocardial fibrosis, either interstitial or replacement-type, with a predilection for 
the infero-lateral LV wall, has been increasingly reported at post-mortem examination of athletes 
who died suddenly71-73. A recent study about the anatomical substrates of juvenile SD reported a 
prevalence of non-ischemic LV scar of 1.3% among victims of SD at rest and of 25% among victims of 
SD during exercise. According to the study, the non-ischemic LV scar is the most common cause of SD 
during physical activity74. Another recent study which included cases of SD which were referred to 
the St. George’s University of London Cardiac Pathology unit confirmed that an important minority  
(8%) of athletes who died suddenly showed idiopathic fibrosis as the underlying myocardial 
substrate75. 
 The increasing use in the clinical practice of CE-CMR has offered the potential to identify “in 
vivo” potentially arrhythmogenic LV scar tissue. Isolated, non-ischemic LV LGE has been previously 
reported in anecdotic cases or small series of individuals and athletes presenting with repolarization 
abnormalities and/or life-threatening VA 76-78. On the other hand, previous CE-CMR studies in 
asymptomatic athletes reported a prevalence of LV LGE ranging from 0 to 50% so that the association 
between the LV scar and VA remains to be proven79-89 (Table 3).  
 The etiology of the LV scar is also a matter of debate. Traditionally, the presence of non-
ischemic LV LGE with an epicardial/midmyocardial distribution and preferential involvement of the 
infero-lateral LV regions is interpreted as the consequence of a previous myocarditis 90-91. However, 
other disease such as the left-dominant variant of ARVC can account for this LGE pattern at CE-CMR 
in the absence of the typical morpho-functional abnormalities of the right ventricle. 
 The classic “right dominant” ARVC phenotype is characterized by prevalent right ventricular 
involvement with progressive fibro-fatty substitution of the ventricular myocardium, particularly in 
  
Table 3 - Prevalence of late gadolinium enhancement in previous cardiac magnetic resonance studies on healthy athletes  
Reference N° cases Mean 
age 
Males Controls Inclusion criteria % LGE LGE patterns in cases 
Mousavi et al. 2009  14 33 y 57% NO Marathon runners, 
moderately trained 
0 %  
Mohlenkamp et al. 2008  
Breuckmann et al. 2009 
102 57 y 100% YES Marathon runners (≥5 
marathons in the last 3 
years), age >50 y old, 
12% 
(4% controls) 
5: subendocardial 
7: midmyocardial spot 
 
O’Hanlon et al.2010 17 
 
34 y 100% NO Marathon runners, mean 
7 hours training/week 
0%  
Oomah et al. 2011 15 32 y 47% NO Half marathon runners, 
non-elite 
0%  
Wilson et al. 2011 12 57 y 100% YES Endurance elite, various 
sports, >50y old 
50% 
(0% controls) 
4: junctional 
1: subendocardial 
1: subepicardial stria 
La Gerche et al. 2012 40 
 
37 y 90% NO Endurance, > 10 
h/training, high 
performance 
13% 1: Junctional 
4: spots in the septum 
Erz et al. 2013 
Mangold 2013 
 
95 35 y 77% NO Endurance, >7 h/week for 
>2y  
2.1% 1: inferior wall spot 
1: lateral wall spot 
Franzen et al.2013 40 41 y 100% NO Triathlon running, >5 
h/week for >2 y 
0%  
Bohm et al. 2016 33 29 y 100% YES Endurance athletes, >10 
h/week for >10 years 
3% 
(0% controls) 
1: subepicardial stria 
LGE=late gadolinium enhancement; y=years 
 
INTRODUCTION 
31 
 
the so-called “triangle of dysplasia” (outflow tract, apex and inflow). Electrical abnormalities 
secondary to the fibro-fatty scarring process are the basis for the typical ECG changes of ARVC                             
including T-wave inversion that can be found in up to 90% of affected individuals do that ECG pre-
participation screening has a high sensitivity for classic ARVC. Moreover, the physiopathological 
process of progressive myocyte loss causes a gradual dilation and systolic dysfunction of the right 
ventricle that can be demonstrated by standard echocardiography. 92. 
 Instead, the “left dominant” variant is characterized by an early and predominant LV 
involvement, as a result of a specific genetic background. At variance with the classic “right-
dominant” variant, the diagnostic power of traditional investigations such ECG and standard 2-D 
echocardiography for “left-dominant” ARVC is limited because ECG changes and LV systolic 
dysfunction, either regional or global, is found in a minority of patients with this variant. The reason 
is that the fibro-fatty scarring process initially involves the sub-epicardial myocardial layers, which 
contribute marginally to the development of the contractile power and does not translate into 
prominent wall motion or electrical abnormalities. As a consequence, the “left-dominant” ARVC 
phenotype is difficult to diagnose and its incidence is probably underestimated. CE-CMR identifies 
non-transmural LV areas of LGE at a subepicardial and/or mid-mural level in the majority of affected 
patients, but the exam is expensive and not widely available and it is not routinely performed to 
apparently healthy young individuals and athletes93.  
 Not surprisingly, the incidence of SD secondary to the classic ARVC variant has markedly 
decreased after the introduction of ECG pre-participation screening, while the difficult-to-diagnose 
“left dominant” variant is now among the most common causes of SD94 (the most popular example 
being the professional soccer player Pier Mario Morosini, who died while playing a match in 2012).
 As the majority of patients affected by “left-dominant” ARVC suffer from arrhythmias 
originating from the LV, 24-hours recording of the ECG may improve the diagnostic sensitivity for this 
disease among apparently healthy athletes with no suspicious findings at standard pre-participation 
screening, but this exam is not part of routine investigations of athletes. 
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AIMS 
 The research project includes three different studies that were performed during the three 
years of the PhD program. 
 The aim of the first study was to evaluate the incidence, relation to physical exercise and 
causes (with particular reference to non-ischemic left ventricular scar) of out-of-hospital cardiac 
arrest (OHCA) of presumed cardiovascular origin, which occurred in the Padua province in individuals 
1-40 years-old. The incidence of OHCA was calculated both in the overall population and according to 
the athletic status. The study results are still unpublished. 
 The second study aimed to characterize the clinical profile and outcome of a cohort of 
competitive athletes with apparently idiopathic VA who showed isolated non-ischemic LGE on CE-
CMR. The CE-CMR features and outcome of the index athletes were compared with those of athletes 
with frequent premature ventricular beats (PVBs) or complex VA and no LGE and control healthy 
athletes in order to assess whether the presence, specific morphologic pattern, regional localization 
and wall distribution of the LGE are associated with an increased arrhythmic risk. The study has been 
published in Circulation: Arrhythmias and Electrophysiology in 201695.  
 The third study aimed to investigate the prevalence, morphology, determinants and 
underlying substrate (as assessed by echocardiography and contrast-enhanced CMR) of frequent 
PVBs/complex VA at 24-hours 12-leads ambulatory ECG monitoring in apparently healthy athletes 
who have been considered eligible for competitive sports activity at preparticipation screening within 
1 year. The purpose was to evaluate whether a strategy consisting of the 24-hours 12-leads 
ambulatory ECG monitoring as a first-line investigation and CE-CMR as a second line investigation 
may improve our ability to identify a concealed LV scar in apparently healthy athletes. The study 
results are still unpublished. 
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METHODS 
1. Incidence and causes of OHCA of presumed cardiovascular origin in the 
Padua province 
Inclusion criteria 
 The study population included all residents in the province of Padua 1-40 year-old who 
suffered OHCA, either resuscitated (“aborted” SD) or not (“SD”), of presumed cardiovascular origin 
during the period 2011-2015. Data were collected from the database of the Emergency Medical 
System (SUEM-118) of the Padua province, which is the only responsible for provision of first aid in 
Italy and that collects all emergency medical calls. At the time of the study the population of the 
Padua province 1 to 40 years of age was 380.866 inhabitants (48.6% males) (Data: Office of the 
President of the Padua Province). 
 Cases of SD of the infant (<1 year-old) were excluded because this represents a peculiar 
condition with different pathogenesis96. The cardiac arrest was considered “sudden” if it occurred 
within one hour of symptoms onset in apparently healthy individuals or in non terminally ill patients. 
The cardiac arrest was considered of “presumed cardiovascular origin” at the time of first medical 
contact if the circumstances of the event did not suggest a non natural cause (e.g. trauma, suicide, 
intoxication…) or evident non cardiovascular causes (e.g. hemorrhage…). Hence, subjects who 
suffered OHCA judged to be of “presumed cardiovascular origin” at first medical contact but with a 
final clinical or post-mortem diagnosis of non cardiovascular etiology were included. Finally, the 
OHCA was considered exercise-related if it occurred during or immediately after the cessation of 
exercise. 
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Cardiac arrest and competitive sports activity  
 In Italy all athletes who want to engage in competitive sports activity must undergo 
preparticipation screening including 12-lead ECG and the eligibility decision of the Sports Medicine 
doctor is recorded in a database of the Italian Health System. This database was consulted to 
determine if the OHCA victims underwent a preparticipation evaluation. In this case, we collected 
data on the type of sports activity, eligibility decision and time from the last medical evaluation to 
the event. Only subjects who underwent the last evaluation within an year of the event were 
classified as active “competitive athletes” as, according to the Italian Law, athletes engaged in 
competitive sports active must undergo preparticipation evaluation on a yearly basis. At the time of 
the study, the total number of athletes in the Padua province 40 year-old or younger was 72.567 
(49.001 in the age group 12-35 year-old) (Data: National Olympic Committee – Padua district).  
 
Diagnosis 
 The diagnosis was obtained clinically in victims of OHCA who were successfully resuscitated. 
A diagnosis of “idiopathic ventricular fibrillation” was made in patients with no evidence of structural 
heart disease or ion channel disease after a thorough clinical investigation (including CE-CMR and 
sodium channel blocker test for Brugada syndrome).  
 In Italy, autopsy of victims of SD (failed resuscitation) is not compulsory but can be required 
both by the physician who certified the death or by the judicial authority. In this case, the autopsy 
was performed in the Institute of Cardiovascular Pathology, Dpt. of Cardiac, Thoracic and Vascular 
sciences, University of Padova (director prof. G. Thiene) according to the Guidelines of the European 
Association of Cardiovascular Pathology 97. Victims of SD who did not undergo autopsy and without a 
history of known cardiovascular disease were classified as SD of “unknown cause”. 
  
METHODS 
37 
 
Statistical analysis  
 We calculated the yearly incidence of OHCA of presumed cardiovascular origin in the Padua 
province both in the overall population and according to age and gender.  
 Continuous variables were expressed as median (1st-3rd quartiles) and compared with the 
rank sum test (2 groups) or the Kruskall-Wallis test (>2 groups). Dichotomous variables were 
expressed as N (%) and compared with the chi square test or the Fisher exact test, as appropriate. 
Statistical analysis was performed with SPPS version 17 (SPSS inc. Chicago, ILN). 
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2. Characteristics and outcome of athletes with ventricular arrhythmias and 
LV scar  
 The Inherited Arrhythmogenic Cardiomyopathy unit of the Department of Cardiac, Thoracic 
and Vascular Sciences is a tertiary center for evaluation of young people and athletes with 
established or suspected cardiac disease at risk of life-threatening VA. The present study enrolled a 
series of competitive athletes with frequent PVB (>500/day) or complex VA (sustained or non-
sustained ventricular tachycardia or ventricular fibrillation), which occurred in the absence of 
coronary artery disease, cardiomyopathy and other clinically overt heart disease and were diagnosed 
as “idiopathic” at routine clinical evaluation. All athletes underwent a comprehensive CE-CMR study 
for further imaging assessment and tissue characterization of myocardial substrate.  
 
Breakdown of the study population  
 During the period 2009-2014 a total of 223 competitive athletes who had undergone pre-
participation cardiovascular evaluation by a sports medicine physician were referred to our 
cardiology center for diagnostic evaluation of VA. One-hundred thirty eight athletes were excluded 
from the study because they did not fulfill the enrollment criteria of frequency and complexity of VA 
and did not undergo CE-CMR study. Among the other 85 athletes with frequent PVBs or complex VA, 
8 were excluded because of a diagnosis of structural heart disease including partial anomalous 
pulmonary venous return (N=1), ARVC either definite (N=1) or borderline (N=2), apical HCM (N=1), 
ventricular pre-excitation (N=1) and coronary artery disease (N=2). Four athletes (all with no LGE) 
were lost to follow-up. The athletic study population comprised the remaining 73 athletes with 
frequent PVBs or complex VA and routine diagnostic work-up negative for overt heart disease who 
underwent additional CE-CMR study. According to the CE-CMR findings two groups were identified: 
Group A (N=35) including athletes with VA and evidence of isolated LV LGE and Group B (N=38) 
including athletes with VA and a totally negative CE-CMR study. 
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Controls 
 A group of 40 competitive athletes (Group C) with a negative family history for SCD or 
cardiomyopathy, normal ECG and no VA served as controls. They underwent CE-CMR for further 
imaging assessment of a borderline  (LV wall thickness 12-14 mm) LV hypertrophy found at pre-
participation echocardiography. The CE-CMR study ruled out a pathologic ventricular remodeling due 
to HCM or other structural heart diseases in all. 
 
Clinical investigation  
 At the time of first evaluation, all athletes underwent a routine clinical evaluation including 
family and personal history, physical examination, resting 12-lead ECG, signal-averaged ECG (SAECG), 
12-leads 24-hours Holter monitoring to evaluate morphology of VA, bicycle exercise testing with a 
protocol of 25-50 watt increments every 3 minutes, 2-dimensional transthoracic echocardiography. 
Late potentials on SAECG were defined according to previously proposed criteria98. 
 Additional invasive tests such as coronary angiography (N=36), endomyocardial biopsy 
including molecular pathology investigation for viral genomes (N=6) or programmed ventricular 
stimulation (N=10) were reserved to selected cases.  
 All subjects gave written informed consent after counselling in accordance with the ethical 
standards of the Declaration of Helsinki (2001) and with recommendations given by the Institutional 
Ethical Committee. 
 
Contrast-Enhanced cardiovascular magnetic resonance 
 All athletes were evaluated de novo, with repeated CE-CMR if performed in other 
Institutions, to provide independent diagnosis. 
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Scan protocol 
 CE-CMR was performed on a 1.5-Tesla scanner (Magnetom Avanto, Siemens Medical 
Solutions, Erlangen, Germany) using a comprehensive dedicated protocol. 
 All patients underwent detailed CE-CMR study protocol including post-contrast sequences. 
Images were acquired using a steady-state free precession sequence (true FISP) cine loops in 
sequential short axis views (slice thickness 6 mm, gap 2 mm; repetition time 2.5 to 3.8; echo time 1.1 
to 1.6, average in-plane resolution 1.5x2.4 mm, flip angle 45° to 60°, temporal resolution 40 to 45 
ms) and long- axis views (2-, 3- and 4-chamber views). 
 After intravenous administration of contrast agent (gadobenate dimeglumine, Multihance, 
Bracco, 0.2 mmol/kg of body weight) 2-dimensional segmented fast low-angle shot inversion 
recovery sequence after at least 10 minutes were acquired in the same views of cine images, 
covering the entire ventricles (repetition time 5.4 to 8.3 ms, echo time 1.3 to 3.9 ms, average in-
plane spatial resolution 1.4 to 1.5 x 2.2 to 2.4 mm, 6- mm slice thickness, 2-mm gap, and flip angle 
20° to 25°). Inversion times were adjusted to null normal myocardium using the Look-Locker 
sequence and images were repeated in 2 separate phase-encoding directions to exclude artifacts. 
 
Image analysis 
 Global ventricular volumes, systolic function and LV myocardial mass were calculated from 
the short-axis cine images, excluding papillary muscles from the myocardium, using a dedicated 
software (CMR42, Circle Cardiovascular Imaging Inc). The presence, location and extent of LGE were 
independently assessed by two experienced observers who were blinded to patient clinical data and 
outcome; ambiguous cases were reviewed using a third expert. To exclude artifacts, LGE was deemed 
present only if visible in two orthogonal views (short-axis and long-axis views)using a signal intensity 
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threshold of >2SD above a remote reference region. The pattern of LGE distribution and morphology 
was characterized as either epicardial/midmyocardial “stria” or patchy/junctional “spotty”. If more 
than one pattern was present, the distribution was characterized on the basis of the predominant 
pattern. 
 
Follow-up 
 After the enrollment, patients were followed-up for a mean duration of 38±25 months. The 
primary study end-point was the occurrence of any major arrhythmic events defined as SCD, 
arrhythmic cardiac arrest, sustained ventricular tachycardia or appropriate implantable cardiac 
defibrillators (ICD) intervention on ventricular tachycardia or ventricular fibrillation. Routine ICD 
interrogation and ECG recordings at the time of symptoms were used to document the occurrence of 
spontaneous ventricular tachycardia during follow-up. Sudden cardiac death was defined as any 
natural death occurring instantaneously or within one hour from symptoms onset. Sustained 
ventricular tachycardia was defined as tachycardia originating in the ventricle with rate >100 
beats/minute and lasting >30 seconds or requiring an intervention for termination. Appropriate ICD 
intervention was defined as a device shock or antitachycardia overdrive pacing delivered in response 
to a ventricular tachyarrhythmia and documented by stored intracardiac ECG data. 
 
Statistical Analysis 
 Data are expressed as mean±standard deviation or median with 25 to 75 percentiles for 
normally distributed and skewed variables, respectively. Normal distribution was assessed using 
Shapiro-Wilk test. Categorical differences among groups were evaluated by the chi-square test or the 
Fisher exact test as appropriate. Differences among continuous variables were evaluated with the 
Kruskal-Wallis test. Kaplan-Meier analysis was used to estimate the survival distributions of the 
arrhythmic end-point and to show the differences in survival among groups of patients. Kaplan-Meier 
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curves were compared with the logrank test. Start of follow-up was defined as the date of the initial 
CE-CMR. Patients were followed until the time of their first event or until the time of their last clinical 
follow-up. A value of P<0.05 was considered significant. Statistics were analyzed with SPSS version 19 
(SPSS Inc, Chicago, IL). 
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3. Prevalence, predictors and clinical significance of VA in athletes 
 The “Ventricular Substrates at Cardiac magnetic resonance in Athletes with ventricular 
ARrhythmias (V-SCAAR)” study was carried out at the Center for Sports Medicine, ULSS 16, Padova 
(Director Dr M. Schiavon) during the period August 2015 – September 2016. Volunteers were 
recruited with advertisements in the local sports medicine doctors’ offices, in the social media and in 
local sports society headquarters. The study was reviewed and approved by the Institutional Ethical 
Committee. 
 
Inclusion criteria 
1) age ≥ 16 years-old; 
2) considered eligible to competitive sports activity at preparticipation screening within 1 year of the 
study. According to the Italian Law, the preparticipation screening includes history, physical 
examination and 12-lead ECG. Maximal exercise testing is also required in athletes ≥ 35 year-old; 
3) at least 6 hours of exercise per week; 
4) written consent to participated in all stages of the study (including echocardiography and CE-CMR 
if indicated). If below the age of 18 years, consent of both parents or guardians; 
 
Exclusion criteria 
- engaged in a low static/low dynamic component sport according to the Mitchell classification; 
- pregnancy; 
- CE-CMR in the last three years or contraindication to CE-CMR; 
- cognitive impairment; 
- known cardiac disease (excluding mild valvular disease; previous myocarditis or pericarditis 
which was considered clinically healed or known PVBs in the absence of overt structural heart 
disease). 
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Personal data 
 At the time of enrollment, the following data were collected: age, gender, 
case of multiple sports, the one which accounted for th
considered, hours of training per week during the sporting seaso
training per year (calculated as mean hours of training/week x number of weeks of activity)
sports practice; personal history and family history of coronary artery disease, premature 
year-old in male and <50 year-old in female) or cardiomyopathy.
 
12 leads, 24-Hours ECG monitoring
 All volunteers underwent a 12 leads, 24 hours ambulatory ECG monitoring (H12+™
Instrument Inc, Milwaukee, USA).  
Figure 5. Methods of the V-SCAAR study
Top left: type of ambulatory ECG holter monitoring used in the study. Top right: methodology of ECG 
leads application to minimize the risk of artifacts. Bottom: 24
 
sport practiced (in 
e majority of hours of training was 
n; estimated number of hours of 
 
 
 
-hours heart rate trend 
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 Athletes were instructed to undergo an aerobic training session, possibly of the same sport 
they habitually perform, of at least one hour during the recording. To limit the burden of movement 
artifacts during exercise, the ECG leads were fixed with adhesive tape (Fig. 5). 
 Only recordings of at least 20 hours excluding artifacts and periods of no signal were included 
in the study: in case of <20 hours of recording, the athlete was invited to repeat the study and was 
excluded if he/she denied. The recordings were analyzed with the HScribe 5 software (Mortara 
Instrument Inc, Milwaukee, USA) by the same physician (A. Z.). All families of normal beats and every 
single supraventricular or ventricular ectopic beat were reviewed manually. PVBs were classified 
according to the morphology on the 12 ECG leads as follows: 
- right bundle branch block (RBBB) like (mainly positive QRS complex in V1) or left bundle-branch-
block (LBBB) like (mainly negative QRS complex in V1); 
- superior axis (positive QRS complex in 1 and negative QRS complex in aVF), intermediate axis 
(positive QRS complex in 1 and positive QRS complex in aVF) or inferior axis (negative QRS complex 
in 1 and positive QRS complex in aVF). 
Two distinct ventricular ectopic beats morphologies, that are recognized to be benign in the vast 
majority of cases 99, were identified: 
1) LBBB/inferior axis, suggestive of origin from the right (or left) ventricular outflow tract; 
2) RBBB/left anterior hemiblock or RBBB/left posterior hemiblock and QRS duration ≤130 ms, 
suggestive of fascicular origin. 
 
Second-line clinical investigations 
 Athletes were selected to undergo further diagnostic investigations including 
echocardiography and CE-CMR if they showed: 
1) >29 PVBs, excluding those with morphologies suggestive of right ventricular outflow tract or 
fascicular origin. The cut-off was arbitrarily chosen to balance the limited availability of CE-CMR 
studies that could be performed and the need of a low threshold for CE-CMR prescription to 
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evaluate whether there is a relationship between the number of PVBs count and the risk of an 
underlying LV scar. Patients with distinctively exercise-induced “atypical” PVBs were offered CE-
CMR regardless of the PVBs count; 
 2) ≥1 ventricular couplet (excluding isolated couplets with a morphology suggestive of right 
ventricular outflow tract origin), triplets (any morphology) or non-sustained ventricular 
tachycardia (any morphology). 
 For each athlete with one of the above conditions, a control athlete with no arrhythmias 
matched for gender, age group and type of sports activity according to the Mitchell classification was 
selected and offered echocardiography and CE-CMR. 
 Athletes with frequent PVBS with a morphology suggestive of right ventricular outflow tract 
or fascicular origin or with right ventricular outflow tract couplets were offered echocardiography, 
while CE-CMR was performed only in case of positive findings at echocardiography. 
 Regardless of PVBs count/complexity, clinical investigation such as echocardiography, stress 
echocardiography or CE-CMR were offered to athletes in case of other positive findings suggesting of 
cardiovascular disease (e.g. family history of SD; ECG abnormalities; supraventricular tachycardia; 
dynamic ST-segment depression...) unless they had already undergone CE-CMR within 3 years.  
 The design of the study is summarized in figure 6. 
 
Statistical analysis 
 Data are expressed as median (25th-75th percentile). Categorical differences among groups 
were evaluated by the chi-square test or the Fisher exact test as appropriate. Differences between 
continuous variables were evaluated with the Rank sum test (2 groups) or the Kruskal-Wallis test 
(multiple groups). A binomial logistic regression analysis model was built to identify 
independent predictors of high PVBs count. Variables associated with a p-value <0.15 at 
univariate analysis were entered as covariates in the multivariable model. A value of P<0.05 
was considered significant. Statistics were analyzed with SPSS version 19 (SPSS Inc, Chicago, IL). 
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Figure 6: design of the V-SCAAR study.
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RESULTS 
1. Incidence and causes of OHCA of presumed cardiovascular origin in the 
Padua province 
Incidence and outcome 
 Over the 44 months study period 53 cases of OHCA of presumed cardiovascular origin 
occurred in the Padua province in people 1-40 year-old. Two cases were excluded because they 
occurred in non-residents and 3 because the OHCA circumstances could not be fully established. The 
final study sample included 48 subjected [median age 29 (22-38) year-old]: of those 37 (77%) could 
not be resuscitated and 11 (23%) were admitted alive to the hospital. Eight (17%) were discharged, 
all without neurological impairment. 
 
Figure 7. Incidence rate of out-of-hospital cardiac arrest of presumed cardiovascular origin per 
100.000/inhabitants/year among different age classes and according to gender.  
Y.O.=year-old 
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 The incidence of OHCA in the Padua province was 3.5/100.000 residents/years. The incidence 
of OHCA was significantly higher in men (5.5/100.00/year) compared with females 
(1.4/100.000/year, p<0.001). Moreover, there was a statistically significant association between the 
incidence of OHCA and increasing age (p<0.001) (Fig. 7). The incidence of out-of-hospital SD in the 
age class 12-35 years-old (24 cases) was 2.2/100.000/year.  
  
Causes 
 A final diagnosis was reached in 40 (83%) subjects while in 8 (17%) victims of SD with no 
known cardiovascular disease the autopsy was not performed. The causes of OHCA are listed in table 
4. The most frequent causes were coronary artery atherosclerosis (23%) and structurally normal 
heart (23%). In this last subgroup, a post-mortem family screening allowed to reach a diagnosis of 
Brugada syndrome in 1 while in another 1 the ECG showed short PR interval in the absence of 
ventricular pre-excitation. Seven (10%) subjects were affected by a cardiomyopathy, including 3 
cases of non-ischemic LV scar: 
- a 38 year-old male who died suddenly during exercise. Few months before he underwent CE-CMR 
for chest pain with troponin release and no stenosis of coronary arteries at angiography. The CE-CMR 
study revealed no sign of acute pericarditis (no myocardial edema, no signs of pericardial 
inflammation) but disclosed LV LGE suggesting myocardial scar with a “subepicardial/midmyocardial 
stria pattern” in the infero-lateral LV wall (Fig.8). Autopsy was not performed; 
- a 27 year-old who suffered cardiac arrest after an emotional stress (he was attending the funeral of 
a relative). He was resuscitated and suffered no neurological damage. CE-CMR revealed LV LGE with 
a “subepicardial/midmyocardial stria pattern” in the basal segments of the infero-lateral LV wall. 
Endomyocardial biopsy from the right ventricular apex revealed foci of fibrofatty substitution that 
however, did not fulfill the criteria for the diagnosis of ARVC. He was diagnosed with idiopathic non-
ischemic LV scar (Fig.9);  
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Table 4: causes of out-of-hospital cardiac arrest in the overall sample and in the subgroup of 
patients who died suddenly (failed resuscitation attempts) in the age group 12-35 years-old.  
Cause 
All 
OHCA 
N=40 
Sudden death 
12-35 years-old 
N=19* 
Coronary artery disease 
Coronary stenosis >50% 
Coronary occlusion 
9 (23) 
4 
5 
3 (16) 
1 
2 
Cardiomyopathy 
ARVC 
Hypertrophic cardiomyopathy 
Dilated cardiomyopathy 
Non-ischemic LV scar 
7 (10) 
1 
1 
2 
3 
3 (16) 
0 
1 
1 
1 
Myocarditis 3 (7) 1 (5) 
Mitral valve prolapse# 4 (10) 1 (5) 
Congenital heart disease 
Surgically corrected TGA 
Coronary artery anomaly 
2 (5) 
1 
1 
2 (11) 
1 
1 
Acute pulmonary embolism 3 (7) 0 
Structurally normal heart% 9 (23) 6 (32) 
Non cardiovascular causes 
Asthma 
Brain hemorrhage 
Lymphoma 
3 (8) 
1 
1 
1 
3 (16) 
1 
1 
1 
ARVC = arrhythmogenic cardiomyopathy; LV=left ventricular; TGA=transposition of 
great arteries 
 
* Inclusion criteria of the study by Corrado et al, JACC 2003 
# including one case of posterior mitral leaflet flail in a patient with Marfan syndrome 
% including one case of Brugada syndrome and one of accelerated atrioventricular 
conduction 
  
 
- a 21 year-old male who suffered SD during sleep and was diagnosed with idiopathic LV scar 
involving the subepicardial/midmyocardial layer of the infero-lateral LV wall at autopsy. 
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 Six people were affected by a known cardiovascular disease which was the cause of OHCA: 1) 
a 20 year-old male with HCM (North
year-old female with surgically corrected transpos
dilated cardiomyopathy; 4) a 35 year
with previous chest pain and demonstration of LV
6) a 28 year-old male with mitral valve prolapse and suspected Marfan syndrome (diagnosed at 
sports preparticipation screening 12 years before the event) who suffered acute heart failure and 
ventricular fibrillation due to flail mitral valve.
Figure 8: CE-CMR findings in a victim of sudden death during exercise.
Late post-contrast T2 weighted cardiac magnetic resonance images demonstrating non
(subepicardial/midmyocardial) left ventricular late gadolinium enhancement (suggesting myocardial 
scar) in the mid and basal segments of the infero
-African immigrant who was not regularly followed
ition of great arteries; 3) a 3 year
-old male with dilated cardiomyopathy; 5) the 38 year
-LGE suggestive of myocardial scar at 
 
 
-lateral wall (courtesy of dr. M. Perazzolo Marra). 
-up); 2) a 14 
-old male with 
-old male 
CE-CMR and 
 
-ischemic 
 
 Figure 9: CE-CMR and endomyocardial biopsy in a patient who suffered resuscitated cardiac arrest.
Top: late post-contrast T2 weighted cardiac magnetic resonance i
(subepicardial/midmyocardial) left ventricular late gadolinium enhancement (suggesting myocardial 
scar) in the mid and basal segments of the infero
Bottom: endomyocardial biopsy (Azan) showing foci of fibrofatty substitution 
histomorphometric criteria for the diagnosis of Arrhythmogenic cardiomyopathy (courtesy of prof. C. 
Basso). 
 
Cardiac arrest and competitive sport activity
 Three victims of OHCA
classified as athletes. In all three
player who was resuscitated from cardiac arrest
ventricular fibrillation (structurally normal heart and no signs of ion channel disease). The second is a 
17 year-old who was also resuscitated from cardiac arrest
mages demonstrating non
-lateral wall (courtesy of dr. M. Perazzolo Marra). 
 
 engaged in competitive sports activity at the time of OHCA
 cases the OHCA occurred at rest. The first is a 29 year
 while driving and was diagnosed
 while sleeping. A recent preparticipation 
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-ischemic 
which do not reach the 
 and were 
-old basketball 
 with idiopathic 
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screening revealed negative T-wave in the anterior leads V1-V2: he underwent echocardiography 
which revealed no signs of cardiomyopathy. During the hospitalization he underwent 
endomyocardial biopsy which revealed patchy fibrofatty substitution that fulfill the minor criterion 
for the diagnosis of ARVC. He also underwent CE-CMR that revealed mild right ventricular dilation 
and apical hypokinesis that did not fulfill the imaging criteria for ARVC diagnosis; however, as he had 
T-wave inversion in V1-V2 (minor diagnostic criterion), ventricular fibrillation (major diagnostic 
criterion) and patchy fibrofatty substitution at endomyocardial biopsy (minor diagnostic criterion) he 
received a diagnosis of ARVC100. The last was a 29 year-old who died while sleeping: the autopsy 
revealed a structurally normal heart.  
 Eight (17%) people, all non-athletes, suffered OHCA during physical exercise but none 
occurred during organized sports activity. The incidence of OHCA was significantly lower among 
screened athletes than among non-athletes (1.1/100.000/year vs. 3,9/100.000/year, p<0,001).  
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2. Characteristics and outcome of athletes with ventricular arrhythmias and 
LV scar  
 
Clinical findings 
 The clinical characteristics of the 3 study groups are shown in Table 5. There were no 
statistically significant differences with regard to sex and age among groups. 
Table 5: clinical characteristics of the study population 
 Group A 
VA and LGE 
N=35 
Group B 
VA and NO LGE 
N=38 
Group C 
Controls 
N=40 
P 
Age 33 (25-40) 28 (21-41) 29 (23-36) 0.28 
Sex (male) 28 (80) 27 (71) 33 (83) 0.45 
Sport 
Soccer 
Running 
Volleyball  
Swimming 
Cycling 
Other 
 
8 (23) 
7 (20) 
7 (20) 
3 (9) 
4 (11) 
6 (17) 
 
7 (18) 
9 (24) 
4 (11) 
4 (11) 
10 (26) 
4 (11) 
 
11 (28) 
9 (23) 
6 (13) 
6 (15) 
3 (8) 
5 (13) 
 
0.60 
Family history 
Negative 
Cardiomyopathy 
Premature sudden death 
 
30 (86) 
2 (6) 
3 (9) 
 
37 (97) 
0 
1 (3) 
 
 
 
 
 
0.10 
0.23 
0.34 
Personal history 
Negative 
Cardiac arrest 
Sustained ventricular tachycardia 
Syncope 
Pre-syncope 
Palpitations 
Chest pain 
 
18 (51) 
2 (6) 
5 (14) 
5 (14) 
2 (6) 
8 (23) 
1 (3) 
 
23 (61) 
0 
0 
0 
2 (5) 
14 (37) 
0 
 
 
 
0.43 
0.60 
0.02 
0.02 
1.0 
0.19 
0.48 
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Electrocardiogram 
Normal 
Low (≤ 0.5 mV) QRS in limb leads 
Intraventricular conduction delay  
QRS duration 100-120 ms 
QRS duration >120 ms 
Pathologic Q-waves 
T-wave inversion in V1-V3 
T-wave inversion in V4-V6 ± 1/aVL 
T-wave inversion in 2/aVF/3 
 
22 (63) 
7 (20) 
 
3 (9) 
0 
2 (6) 
1 (3) 
7 (20) 
2 (6) 
 
35 (92) 
1 (3) 
 
2 (6) 
0 
0 
0 
0 
1 (3) 
 
 
 
0.004 
0.02 
 
0.67 
- 
0.23 
0.48 
0.004 
0.60 
Late potentials at SAECG 6/15 (40) 1/20 (5)  0.03 
24-Hours ECG monitoring 
Frequent (>500/day) PVB  
 Couplets and/or triplets 
Non-sustained VT (≥4 PVB)  
Sustained VT/VF 
30 (86) 
20 (57) 
8 (23) 
1 (3) 
35 (92) 
18 (47) 
2 (6) 
0 
 0.47 
0.40 
0.04 
0.48 
Response to exercise testing 
No/suppression 
Isolated PVB 
Repetitive PVB 
 
9 (26) 
16 (46) 
10 (29) 
 
15 (39) 
19 (50) 
4 (11) 
  
0.21 
0.71 
0.07 
Echocardiogram 
Normal 
Regional LV wall motion 
abnormalities 
 
30 (86) 
5 (14) 
 
38 (100) 
0 
 
 
 
0.02 
 
Inducibility at PVS 3/10 (30) -   
Endomyocardial biopsy 
Negative 
Myocarditis 
Fibro-fatty replacement 
 
4/6 (67) 
1/6 (17) 
1/6 (17) 
 
- 
  
ICD implantation 9 (26) -   
EF=ejection fraction; ICD=internal cardioverter defibrillator; LBBB=left bundle branch block, LGE=late 
gadolinium enhancement; LV=left ventricular; PVB=premature ventricular beats; PVS=programmed 
ventricular stimulation; RBBB=right bundle branch block; SAECG=signal averaged electrocardiogram; 
VA=ventricular arrhythmias; VF=ventricular fibrillation; VT=ventricular tachycardia 
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 The Group A included 35 athletes (80% males, mean age 33 years, range 14-48) with frequent 
PVB or complex VA and LGE at CE-CMR. Thirty (86%) had a negative family history for SCD or 
cardiomyopathies. Seventeen athletes (49%) had a positive personal history for ≥1 of the following 
events/symptoms: cardiac arrest (N=2), sustained ventricular tachycardia (N=5), syncope (N=5), pre-
syncope (N=5), palpitations (N=8) and/or chest pain (N=1). No patient had a prior diagnosis of acute 
myocarditis. 
 The ECG was abnormal in 13 (37%) athletes and the most common abnormalities were low 
QRS voltages in limb leads (20%) and T-wave inversion in infero-lateral leads (20%). Signal-averaged 
ECG was positive in 6/15 (40%) athletes. In 28 (80%) athletes, 12-leads 24-hours ambulatory ECG 
monitoring recorded frequent PVB and/or complex VA with a predominant RBBB morphology 
(suggestive of LV origin) with superior axis (N=23), inferior axis (N=3), or intermediate axis (N=2); the 
remaining 7 (20%) had frequent isolated PVBs with a predominant LBBB/inferior axis morphology. On 
stress testing, VA occurred or worsened at the peak of exercise in 26 (74%) athletes. 
Echocardiography was abnormal in 5 (14%) athletes showing hypokinesis of the infero-lateral LV wall. 
Sustained ventricular tachycardia was induced by programmed ventricular stimulation in 3/10 (30%) 
athletes.  
 Endomyocardial biopsy was performed in 6 athletes: histopathological findings were 
consistent with focal acute myocarditis in one, segmental fibro-fatty replacement in two, and were 
normal in the remaining 3. Molecular pathology investigation by polymerase chain reaction (PCR) 
and reverse-transcriptase (RT)-PCR was negative for viral genomes. 
 The Group B included 38 athletes with frequent PVBs or complex VA and no LGE at CE-CMR. 
They significantly less often showed ECG changes, non-sustained ventricular tachycardia at 24-hours 
ECG monitoring and echocardiographic LV wall motion abnormalities compared with athletes of 
Group A. The majority (71%) of athletes of group B had VA with a predominant LBBB/inferior axis 
pattern.  
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Table 6 – Contrast-enhanced cardiac magnetic resonance findings 
 Group A 
VA and LGE 
n = 35 
Group B 
VA and NO 
LGE 
N=38 
Group C 
Controls 
n = 40 
p 
Morpho-functional CMR     
Mild LV dilatation, No. (%) 9 (26) 5 (13) 3 (8) 0.08 
LV EDVi (ml/m2), mean±SD 95 (88-110) 94 (85-108) 92 (82-101) 0.18 
LV EF (%), mean±SD 62 (59-68) 61 (58-66) 60 (57-65) 0.43 
LV mass (g/m2), mean±SD 72 (65-83) 75 (63-80) 80 (69-91) 0.29 
Mild RV dilatation, No. (%) 6 (17) 10 (26) 5 (13) 0.28 
RV EDVi (ml/m2), mean±SD 90 (74-102) 93 (77-105) 90 (75-103) 0.11 
RV EF (%), mean±SD 60 (58-62) 60 (57-66) 58 (55-64) 0.34 
Post-contrast CMR 
RV LGE, No. (%) 
LV LGE, No. (%) 
Patterns 
Epicardial “stria” 
Junctional “spotty” 
Regional distribution of stria 
Anterior wall 
Lateral wall 
Inferior wall 
Septum 
Apex (17° segment) 
 
0 
35 (100) 
 
27 (77) 
11 (31) 
 
4/27 (15) 
24/27 (89) 
7/27 (26) 
3/27 (11) 
3/27 (11) 
- 
- 
 
- 
- 
 
- 
- 
- 
- 
- 
 
 
0 
10 (25) 
 
0 
10 (25) 
 
- 
- 
- 
- 
- 
 
- 
0.001 
 
<0.001 
0.52 
 
- 
- 
- 
- 
- 
*All group A athletes had LV LGE and all group B athletes had no LV LGE by study design 
 
CMR= Cardiac Magnetic Resonance; LGE= Late Gadolinium Enhancement; LV= Left Ventricular; EDVi = 
End-Diastolic Volume index; EF= Ejection Fraction; RV= Right Ventricular; VA=ventricular arrhythmias. 
 
 By study design, the 40 control athletes (Group C) had no VA and a negative routine 
cardiovascular evaluation.  
 
 CMR features  
Findings of cine CMR and tissue characterization CMR sequences are reported in Table 6.
Group A 
 Mild LV dilation with preserved LV ejection fraction was detected in 9 (26%) group A athletes. 
Mild RV dilation in the absence of RV dysfunction was detected in 6 (17%) cases. At post contrast 
sequences, 27 (77%) showed an epicardial/midmyocardial “stria” 
associated with a junctional “spotty” LGE (i.e. LGE spot at the insertion points of the RV free wall to 
the interventricular septum) in 5 
 The subepicardial/midmyocardial “stria” was localized in the lateral LV 
patients, in isolation or in association with other regions. Three patients showed isolated 
involvement of the LV apical segments. The remaining 8 (23%) index athletes had isolated junctional 
“spotty” LGE at the posterior junction (N=7) or 
patients exhibited right ventricular
 Among the 27 athletes with a “stria” pattern, 5 (19%) had a positive family history, 8 (30%) a 
history of sustained ventricular tachycardia
echocardiographic abnormalities compared with none of the 8 index athletes with isolated junctional 
pattern of LGE, which was 
(Fig. 10 and 11).  
at both the anterior and posterior junctions (N=1). No 
 LGE. 
 
 or cardiac arrest, 13 (48%) ECG changes, 5 (19%) 
Figure 10: A 42 years
player presenting with frequent and 
coupled premature ventricular beats 
with right bundle branch block/superior 
axis morphology during exercise testing
(A). The athlete experienced sustained 
ventricular tachycardia during follow
(B). Contrast-enhanced cardiac magnetic 
resonance revealed a 
subepicardial/midmyocardial “stria” of 
late-gadolinium enhancement involving 
the antero-lateral, lateral and infero
lateral left ventricular wall (C).
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“spotty” LGE. Moreover, all 27 athletes with a “stria” pattern had 
morphology (suggestive of LV origin)
“spotty” pattern. 
 
Group B 
 Mild LV and RV dilatation, in the absence of ventricular systolic dysfunction, was found 
respectively in 5 (13%) and 10 (26%) athletes of group B. 
Group C 
 Mild LV dilation in the absence of LV dysfunction was found in 3 of 40 (8%) controls. Mild 
right ventricular dilation in the absence of 
controls. At post-contrast sequences, 10 (25%) controls showed LV LGE, all with a junctional “spotty” 
Figure 11: A 23 years-old soccer player who suffered syncope during a match. 
Contrast-enhanced cardiac magnetic resonance revealed a subepicardial/
of late-gadolinium enhancement involving the lateral left ventricular wall (A). Twelve
showed T-wave inversion in the infero
patient received an ICD because of sustained 
ventricular stimulation. After 13 months, he experienced an ICD shock on fast (tachycardia cycle 
length 200 ms) ventricular tachycardia while he was playing table tennis (C).
VA with a predominant RBBB 
 compared with 1/8 (13%) of those with an isolated junctional 
 
right ventricular dysfunction was detected in 5 (13%) 
 
midmyocardial “stria” 
-lateral leads and premature ventricular beats (B). The 
ventricular tachycardia inducibility by programmed 
 
-lead ECG 
 pattern. The junctional LGE spot was localized in the posterior
with anterior junction (N=2). No control exhibited 
Comparison among groups 
 At cine CMR, morpho
epicardial/midmyocardial “stria” pattern was distinctively observed in athletes with 
while the prevalence of junctional “spotty” LGE was similar in athletes of Group A and controls 
12).  
 
  
 
Follow-up 
 Thirty-two athletes were restricted from competitive sports activity including all 27 i
athletes with arrhythmias and a subepicardial/midmyocardial “stria” pattern of LGE, 1 athlete with 
complex VA and isolated junctional “spotty” pattern, and 4 athletes with complex, exercise
VA and no LGE. Twenty five athletes with demonstratio
LGE were prescribed beta blockers and 9 group A athletes received an ICD for either secondary 
Figure 12: Short axis post-
with frequent premature ventricular beats with a left bundle branch block/inferior axis 
morphology (suggestive of right ventricular outflow tract origin)
(A) and in a 31 year-old healthy marathon runner without arrhythmias (B) showing 
gadolinium enhancement with a “spotty” pattern at the inferior insertion point of the right 
ventricular free wall to the interventricular septum
 
 junction, alone (N=8) or associated 
right ventricular LGE. 
-functional features did not significantly differ among the 3 groups. The 
n of exercise-inducible LV arrhythmias and LV 
contrast cardiac magnetic resonance views of a
. 
. 
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 27 year-old rower 
late-
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prevention (cardiac arrest N=2; spontaneous sustained VT N=5) or primary prevention (syncope and 
inducible ventricular tachycardia by programmed ventricular stimulation, N=2). 
 During follow-up, 6 patients (all with a subepicardial/midmyocardial “stria” of LV LGE) 
experienced major arrhythmic events including appropriate ICD shocks 
ventricular tachycardia (N=1). Five of six events occurred during exercise.
programmed ventricular stimulation that was positive for sustained VT induction in 2.
had a progressive LV dysfunction 
transplantation 5 years after initial evaluation (Fig
Fig. 13: A 18-years-old tennis player who underwent contrast
resonance for infero-lateral T-wave inversion at baseline 12
ventricular ectopic beats with a right bundle branch block/superior axis at exercise testing (B).
Cardiac magnetic resonance revealed subepicardial/midmyocardial late
with a “stria pattern” involving the infero
developed progressive left ventricular dysfunction that led to refractory heart failure and heart 
transplantation. Panoramic view of the infero
showed extensive replacement-type fibrosis mostly in the subepicardial and mid
with focal fatty infiltration (trichrome heidenhain stain) (D). At higher magnification, the residual 
cardiomyocytes are hypertrophic and show dysmetric and dysmorphic nuclei, 
vacuolization: note the diffuse fibrosis and patchy fatty infiltration (Haematoxylin
 
(N=4), SD (N=1) and sustained 
 Three of them underwent 
leading over time to end-stage heart failure requiring heart 
. 13).  
-enhancement cardiac magnetic 
-lead ECG (A) and frequent 
-gadolinium enhancement 
-lateral left ventricular wall (C). During follow
-lateral left ventricular wall of the removed heart 
with cytoplasmic 
-
 One patient 
 
 
-up he 
-mural layers, 
eosin stain) (E). 
  Both the athlete who died suddenly and the one who underwent heart tran
pathologic evidence of biventricular subpicardial and/or mid
distribution in keeping with a diagnosis of “left dominant” ARVC.
  A familial recurrence of the LV LGE was ascertained in two cases. The fir
died suddenly. CE-CMR study demonstrated inferolateral LV LGE “stria” in his asymptomatic brother 
who was also a cyclist. The second was a volleyball player who sought medical attention because of 
frequent PVBs. The CE-CMR showed a n
lateral and the inferior LV free wall. The same CE
identical twin brother (Fig. 14
 Kaplan Meier analysis of freedom from malignant arrhythmias during follow
major arrhythmic events distinctively occurred in the subset of athletes with 
of LV LGE at the time of enrollment 
 
-mural fibro-fatty replacement, with a 
 
on-ischemic LV LGE with a “stria” pattern involving both the 
-CMR features were observed in his asymptomatic 
). 
 
(Fig. 15). 
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st was the cyclist who 
-up showed that 
VA and a “stria” pattern 
Figure 14: long axis 
(A,C) and short axis 
(B,D) post-contrast 
cardiac magnetic 
resonance views of 
two 34-years old 
identical twin 
brothers showing a 
subepicardial/midm
yocardial “stria” of 
late-gadolinium 
enhancement 
involving the lateral 
and infero-lateral 
left ventricular wall. 
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Fig. 15: Kaplan-Meier analysis for survival from major arrhythmic events 
(A) Kaplan-Meier analysis for survival from major arrhythmic events in athletes with ventricular 
arrhythmias and late gadolinium enhancement (LGE), in athletes with ventricular arrhythmias an
no LGE, and in controls (with or without “spotty” LGE) (B) Kaplan
major arrhythmic events in the subgroup of athletes with ventricular arrhythmias and LGE 
according to specific LGE patterns (“stria” versus “spotty”).
 
 
-Meyer analysis for survival from 
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3. Prevalence, predictors and clinical significance of VA in athletes 
Characteristics of the study sample 
 The study population included 384 athletes with no history of structural heart disease who 
successfully completed at least 20 hours of recording (excluding artifacts and no-signal time) at 12-
leads ambulatory ECG recording. The characteristics of the study sample are shown in table 7.  
Table 7 – Characteristics of the study sample 
 N=384 
Median age (years) 29 (20-42) 
Age classes 
16-20 year-old 
21-25 year-old 
26-35 year-old 
36-45 year-old 
>45 year-old 
 
116 (30.2%) 
59 (15.4%) 
70 (18.2%) 
67 (17.4%) 
72 (18.8%) 
Male gender 294 (77%) 
Hours of practice/week 8 (6-9) 
Hours of practice/week, classes 
6-9 hours/week 
10-13 hours/week 
>14 hours/week 
 
261 (68.0%) 
101 (26.3%) 
22 (5.7%) 
Hours of practice/year 350 (312-450) 
Hours of practice/year, classes 
<350 hours/year 
350-600 hours/year 
>600 hours/year 
 
206 (53.6%) 
122 (31.8%) 
56 (14.6%) 
Years of sport activity 9 (5-16) 
Years of sport activity, classes 
< 6 years 
6-10 years 
>10 years 
 
108 (28.1%) 
129 (33.6%) 
147 (38.3%) 
Type of sport (Mitchell classification)  
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IB (low static - mod. dynamic) 
IC (low static - high dynamic) 
IIB (mod. Static - mod. dynamic) 
IIC (mod-static - high dynamic) 
IIIA (high static – low dynamic) 
IIIB (high static – mod. dynamic) 
IIIC (high static – high dynamic) 
31 (8.1%) 
142 (37.0%) 
25 (6.5%) 
44 (11.5%) 
14 (3.6%) 
10 (2.6%) 
118 (30.8%) 
Family history 
Negative 
Premature sudden death 
Coronary artery disease 
Cardiomyopathy 
 
271 (70.6%) 
16 (4.2%) 
92 (24.0%) 
4 (1.0%) 
 
Premature ventricular beats 
 The 12-leads ambulatory ECG monitoring recorded at least one PVB in 169 (56%) athletes. 
The distribution of percentiles of PVBs count according to the morphology is shown in table 8.  
Table 8 - distribution of %iles of premature ventricular beats count according to the morphology 
 5thiles 10 thiles 25 thiles 50 thiles 75 thiles 90 thiles 95 thiles 
LBBB 0 0 0 0 1 6 49 
Inferior axis 0 0 0 0 1 2 19 
Interm. axis 0 0 0 0 0 0 1 
Superior axis 0 0 0 0 0 2 3 
RBBB 0 0 0 0 1 4 22 
Inferior axis 0 0 0 0 0 1 3 
Interm. axis 0 0 0 0 0 0 1 
Superior axis 0 0 0 0 1 3 6 
All 
morphologies 
0 0 0 1 4 30 212 
Excluding 
RVOT/Fascicular 
0 0 0 1 2' 7 25 
LBBB=left bundle branch block; RBBB=right bundle branch block; RVOT=right ventricular outflow 
tract 
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Thirty-eight athletes (9.9%) showed >29 PVBs/day and 17 (4.4%) >29 “uncommon” PVBs/day (i.e. 
excluding PVBs with a morphology suggestive of fascicular or right ventricular outflow tract origin). 
The univariate and multivariate analyses for predictors of >29 PVBs/day (both counting all 
morphologies and excluding morphologies suggesting right ventricular outflow tract/fascicular origin) 
are shown in Table 9-12.  
Table 9 – characteristics of the study sample according to the presence of >29 PVBs/day (any 
morphology) 
 ≤29 PVBs/day 
N=346 
>29 PVBs/day 
N=38 
P 
Age 26 (19-41) 43 (31-48) <0.001 
Male gender 263 (76%) 31 (82%) 0.44 
Hours of practice/week 8 (6-9) 8 (6-10) 0.30 
Hours of practice/year 340 (312-420) 390 (310-520) 0.09 
Years of sport activity 9 (5-15) 15 (6-28) 0.009 
 
 
Table 10 . multivariate analysis for predictors of the presence of >29 PVBs/day (any morphology) 
 OR 95% C.I. P 
Age 1.05 1.02-1.08 0.02 
Hours of practice/year 1.00 0.99-1-01 0.21 
Years of sport activity 1.02 0-99-1.06 0.20 
 
 
Table 11 – characteristics of the study sample according to the presence of >29 “uncommon” 
PVBs/day (excluding morphologies suggesting right ventricular outflow tract/fascicular origin) 
 
≤29 PVBs/day 
N=367 
>29 PVBs/day 
N=17 
P 
Age 27 (19-42) 45 (36-51) 0.001 
Male gender 279 (76%) 15 (88%) 0.38 
Hours of practice/week 8 (6-9) 9 (7-10) 0.19 
Hours of practice/year 350 (310-430) 380 (306-520) 0.21 
Years of sport activity 9 (5-16) 13 (7-34) 0.07 
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Table 12 - multivariate analysis for predictors of the presence of >29 “uncommon” PVBs/day 
(excluding morphologies suggesting right ventricular outflow tract/fascicular origin) 
 OR 95% C.I. P 
Age 1.05 1.02-1.08 0.002 
Years of sport activity 1.03 0.99-1.06 0.14 
At multivariate analysis, age was the only independent predictor of high PVBs count (Fig.16) 
 
 
 
Repetitive ventricular arrhythmias 
 Twenty-six (6.8%) athletes showed repetitive VA such as couplets (N=21, 5.5%), triplets (N=4, 
1.0%) and non-sustained ventricular tachycardia of maximum 6 beats (N=8, 2.1%). Eight athletes 
exhibited isolated couplets with a LBBB/inferior axis morphology (suggesting origin from the right 
ventricular outflow tract) (Table 13). Age was the only predictor of the presence of repetitive 
ventricular arrhythmias at 24-hours 12-leads ECG ambulatory monitoring (Table 13 and Fig. 17). 
 
2,6% 3,4%
11,4%
16,4%
19,4%
0,9%
1,7%
2,9%
9,0% 9,7%
0,0%
5,0%
10,0%
15,0%
20,0%
25,0%
16-20 y.o. 21-25 y.o. 26-35 y.o. 36-45 y.o. >45 y.o.
Any PVB >29/day
Atypical PVB >29/day
Figure 16: Prevalence of >29 PVBs/day considering any morphology and only “uncommon” 
morphologies (i.e. excluding morphologies suggesting right ventricular outflow tract/fascicular 
origin) according to age class. 
Any PVBs > 29/day 
“Uncommon” PVBs >29/day 
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Table 13: prevalence and type of repetitive ventricular arrhythmias such as couplets, triplets and 
non-sustained ventricular tachycardia (NSVT) 
 N. of patients % of patients 
≥1 Couplet 21 5.5% 
LBBB-like 13 3.4% 
RBBB-like 9 2.3% 
≥1 Triplet 4 1.0% 
LBBB-like 2 0.5% 
RBBB-like 2 0.5% 
≥ NSVT 8 2.1% 
LBBB-like 3 0.8% 
RBBB-like 5 1.3% 
Any repetitive VA 26 6.8% 
LBBB=left bundle branch block; RBBB=right bundle branch block; VA=ventricular arrhythmias 
Table 14 – characteristics of the study sample according to the presence of repetitive ventricular 
arrhythmias (VA) 
 No repetitive VA 
N=358 
Repetitive VA 
N=26 
P 
Age 27 (19-42) 36 (24-46) 0.04 
Male gender 274 (77%) 20 (77%) 0.96 
Hours of practice/week 8 (6-9) 8 (6-9) 0.17 
Hours of practice/year 350 (312-450) 313 (300-426) 0.29 
Years of sport activity 9 (5-16) 10 (5-26) 0.90 
 
 
4,3% 3,4%
8,6%
10,4%
8,3%
0,0%
5,0%
10,0%
15,0%
20,0%
25,0%
16-20 y.o. 21-25 y.o. 26-35 y.o. 36-45 y.o. >45 y.o.
Repetitive VA
Figure 17: Prevalence 
of repetitive 
ventricular 
arrhythmias (VA) such 
as couplets, triplets 
and non-sustained 
ventricular tachycardia 
according to age class. 
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Echocardiography and CE-CMR findings
 The breakdown of patients referred for second line investigations is shown in Figure 18.
 
 Ten (2.6%) patients were offered 
juvenile SD (N=1), ECG abnormalities (N=2,
inversion in V1-V3, respectively) and frequent PVBs/couplets with a morphology suggestive of right 
ventricular outflow tract/fascicular origin (N=5). Echocardiography was negative in all but one: in a 
42-year old female runner with a family history of SD of unknown origin of a
dilated cardiomyopathy in the mother, right ventricul
athlete was prescribed CE-CMR, that confirmed the right ventricular apical akinesia and showed a 
midmyocardial “stria” of LGE involving the mid inferior LV segments (Fig. 19)
further evaluation to the Inherited Cardiomyopathy clinic.
Figure 18 – Breakdown of patients undergoing second
12-lead ambulatory ECG monitoring
 
 
echocardiography only (N=8) because of family history of 
 consisting in right ventricular hypertrop
 35 year
ar apical akinesia was identified so that the 
. She was referred for 
 Two patients with exercise
-line evaluation after 24
. 
 
 
hy and T-wave 
-old sister and of 
-induced ST-
-hour 
 segment depression during exercise underwent exercise
myocardial ischemia. 
 Twenty-eight (7.3%) athletes showed >29/day “atypical” PV
“atypical” PVBs and/or complex 
and thus fulfilled the criteria for undergoing echocardiography and CE
with no or few (<10/day) PVBs served as controls. The CE
  
  
 Of the 28 subjects who 
showed relevant morpho-functional abnormalities
negative family and personal history and no symptoms,
was revealed (Table 17). The CE
 
 
 
 
Figure 19 – Post-contrast cardiac magnetic resonance sequence, short axis (A) and 
three chambers long axis (B) views in a 42
history of sudden death.
The exam revealed a 
ventricular segments. The 24
 
-echocardiography that was negative for 
Bs/day and/or exercise
VA (excluding isolated couplet with a LBBB/inferior axis morphology) 
-CMR. Twenty
-CMR was technically satisfactory in all.
were prescribed echocardiography and CE-CMR 
. However, in three athletes
 LV-LGE suggestive of non
-CMR was completely negative in all 28 controls.
-year old female runner with a family 
 
midmyocardial “stria” of LGE involving the mid inferior left 
-hour ambulatory ECG monitoring was negative.
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-eight athletes 
 
 
because of VA, none 
, all males and with 
-ischemic LV scar 
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Figure 20 – Non-ischemic left ventricular
Post-contrast cardiac magnetic-resonance, short axis and three chambers long axis views at 
baseline (A-B) and after six months of follow
enhancement  with a subepicardial/midmyocardial distribution (suggesting non
involving the basal portion of the infero
monitoring (E) demonstrated rare but exercise
bundle-branch-block/superior axis configuration, consistent with the origin from the scar area.
 
Figure 21 – Left ventricular late enhancement
Post-contrast cardiac magnetic-resonance three chambers long axis view (A) demonstrating an 
intramural “stria” of late gadolinium enhancement  involving the basal portion of the infero
left-ventricular wall. The ambulatory ECG monitoring (B
ventricular couple and a run of non
 
 late enhancement in a 17 year-old runner.
-up (C-D) demonstrating a “stria” of late gadolinium 
-
-lateral left ventricular wall. The ambulatory ECG 
-induced ventricular arrhythmias with a right
 in a 30 year-old basketball player.  
-C) demonstrated an exercise
-sustained ventricular tachycardia of 4 beats at rest. 
 
 
  
ischemic origin) 
-
 
-lateral 
-induced 
 
  
 
 
Table 17 – Characteristics of the three athletes with presence of non
Age, sport ECG 
17 year-old 
Running 
Negative 
30 year-old 
Basketball 
Negative 
27 year-old 
Soccer 
TWI V4-V6, 
II,III,aVF 
PVB=premature ventricular beats, 
Figure 22 – Left ventricular late enhancement 
Post-contrast cardiac magnetic
demonstrating an intramural “stria” of late gadolinium enhancement  involving the mid and basal 
segments of the inferior left ventricular wall. The baseline ECG demonstrated infero
inversion that was considered benign at the time of preparticipation screening because of 
negative echocardiography. The ambulatory ECG monitoring recorded frequent isolated 
monomorphic premature ventricular beats and rare couples with the same morphology (right 
bundle branch block, inferior axis) (D) suggestive of an origin from the late enhancement site. 
 
 
-ischemic left
ECG monitoring 
Baseline: 53 isolated PVBs (RBBB/superior 
axis)   
6-months FU:  15 isolated PVBs, 2 couples 
and 1 triplet (RBBB/superior axis) 
1 couple (LBBB/superior axis) 
1 run of 4 PVBs (RBBB/superior axis) 
747 isolated and 4 couples (RBBB/superior 
axis) 
LBBB=left bundle branch block, RBBB=right bundle branch block.
in a 27 year-old soccer player
-resonance, short axis (A) and three chambers long axis (B) views 
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-ventricular scar 
Exercise 
induced 
Figure 
 
Yes 20 
Yes 21 
No 22 
.  
-lateral T-wave 
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DISCUSSION 
1. Juvenile cardiac arrest in the Padua province 
 The study included all cases of juvenile OHCA of presumed cardiovascular origin in the 
province of Padua in people 1-40 year-old, Veneto region, over a 4-years period, and demonstrated 
that the event is very rare under the age of 14 (0.7/100.000/year) but becomes relatively frequent 
between 15 and 30 year-old (4.0/100.000/year) and over 30 year-old (5.5/100.000/year). 
 A previous study about the incidence of SD of cardiovascular origin in the Veneto region in 
the age group 12-35 year-old among athletes and non-athletes during the period 1979-2004 
demonstrated that at the beginning of the 80’s the incidence of SD among athletes was 
4.0/100.000/year. However, after the introduction of compulsory preparticipation screening in 1982, 
the incidence of SD among athletes progressively declined as to reach 0.4/100.000/year at the end of 
the study period. At the same time, the incidence of SD among non-athletes remained stable around 
1/100.000/year1. 
 The incidence of SD in the past and present study are not comparable because of the 
different age range and because the present study included all cases of OHCA (both resuscitated and 
not) of presumed cardiovascular origin while the past study included only cases of SD in which a 
cardiovascular disease was confirmed at postmortem investigation; however, it is of note that also in 
the present study the incidence of OHCA of presumed cardiovascular origin among screened athletes 
was significantly lower compared to unscreened non-athletes and that no athlete suffered OHCA 
during exercise. 
 Previous data demonstrated that cardiomyopathies were the most frequent causes of 
juvenile SD in the Veneto region in the 80’s and 90’s, particularly HCM and ARVC, followed by 
ischemic heart disease1, 3. The decrease in SD rate observed among athletes after the implementation 
of preparticipation screening was mainly due to the reduction of deaths due to cardiomyopathies, 
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which showed a decline from 36% to 16% throughout the study period1. The present study, which 
was performed in the modern era, showed that structurally normal heart and coronary artery 
disease were the most common causes of OHCA in the young and, in line with other recent studies, 
they appear to have surpassed the more traditional causes of SD (Table 2), perhaps because early 
identification of these conditions and risk stratification is more difficult. Moreover, it is of note that 
cardiomyopathies accounted for 10% (N=7) of juvenile OHCA in this study but only one case of HCM 
(a North-African immigrant whose previous clinical history was unknown) and one case of mild ARVC 
were diagnosed. Instead, the most frequent cardiomyopathy which accounted for OHCA in the Padua 
province in the modern era was the non-ischemic LV scar with a subepicardial/midmyocardial “stria” 
pattern. 
 
2. LV scar (as suggested by LGE at CE-CMR) and ventricular arrhythmias 
 The analysis of morphology, regional location and wall distribution of LV LGE, both in the 
athletes presenting for VA and in control healthy athletes, allowed to identify two different patterns 
of non-ischemic LV LGE scar: “stria” and “spotty”. The “stria” LGE pattern had a 
subepicardial/midmyocardial wall distribution, mostly (89%) the infero-lateral wall segments and was 
distinctively found in the group of athletes with VA. It was often associated with a history of 
sustained ventricular tachycardia or cardiac arrest and ECG changes such as low QRS voltages in limb 
leads and T-wave inversion in infero-lateral leads, and predicted a malignant arrhythmic outcome. Of 
note, 85% of athletes with a LGE “stria” pattern showed VA with a RBBB/superior axis configuration. 
This morphology is consistent with the origin of the arrhythmia from the infero-lateral LV segments, 
which was the region most frequently affected by LGE. The junctional “spotty” LGE pattern was 
typically localized in the basal segment of the inferior ventricular septum and the junction with the 
right ventricular free wall and was not associated with abnormal history or ECG findings and 
arrhythmic events during follow-up. Moreover, the majority of patients with isolated junctional 
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“spotty” LGE exhibited a LBBB/inferior axis arrhythmia configuration, suggesting that the arrhythmia 
originated from the right ventricular outflow tract and was unrelated to the LGE site. Similarly, 
athletes with arrhythmias but no LV LGE showed PVBs with a predominant LBBB morphology and an 
uneventful follow-up. Pooled together, these findings suggest that the combination of ventricular 
arrhythmias with a predominant RBBB morphology and LV LGE with a “stria” pattern identifies a 
clinical scenario at risk of malignant arrhythmic events during follow-up. 
 In our population of athletes with LV arrhythmias and non-ischemic LV LGE with a “stria” 
pattern, echocardiographic hypokinesis of the inferolateral LV segments involved by the 
subepicardial/midmyocardial scar as evidenced by CE-CMR was found in 5/27 (29%) patients. This 
finding is in keeping with the results of a previous study on a small series of athletes showing that 5 
of 7 with subepicardial LGE had a normal echocardiography78. That non-ischemic LV scar is 
undetectable by echocardiography may be explained by the segmental nature of myocardial fibrosis 
confined to small myocardial area and involving outer wall layers without reaching the 
subendocardium, which is the part of the LV that contribute the most to myocardial thickening101. It 
is noteworthy that non-ischemic LV scar as evidenced by CE-CMR accounted for life-threatening 
arrhythmic events including SD during follow-up, despite the largely preserved global LV systolic 
function. 
 
3. 12-leads ambulatory ECG monitoring for identification of concealed LV scar 
 The study aimed to prospectively evaluate a new protocol for pre-symptomatic diagnosis of 
concealed arrhythmogenic myocardial scar. The protocol consisted in offering 24-hours 12-leads 
ambulatory ECG monitoring (ECG-Holter) to apparently healthy athletes who have been considered 
eligible to competitive sports activity less than 1 year before enrollment. If the ECG-Holter recorded 
>29/day PVBs with uncommon morphologies (i.e. excluding fascicular and right ventricular outflow 
tract PVBs) or repetitive VA, CE-CMR was performed to rule out an underlying LV scar. To the best of 
our knowledge, this is the first study that performed 12-leads ECG-Holter to apparently healthy 
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volunteer athletes rather than athletes that were referred because of PVBs at preparticipation 
screening or palpitations102-105. 
 At multivariate analysis, the presence of frequent PVBs (both of any morphology and only 
considering “uncommon” morphology) or repetitive VA significantly correlated with increasing age 
but not with the amount of sports activity.  
 In younger athletes (<35 year-old), even a relatively small number of PVBs may be related to 
an underlying LV scar and cannot be dismissed as normal finding. The results of our study suggest 
that in this age group more than the number, it is the morphology and relation to exercise of PVBs 
that may suggest the presence of a pathological myocardial substrate as suggested by the fact that 
all three athletes with LV scar at CE-CMR exhibited PVBs with a RBBB-like pattern (suggesting LV 
origin) and two of three distinctively showed exercise-induced arrhythmias. Conversely, the 
prevalence of frequent PVBs of uncommon morphology was higher in athletes over 35 year-old but 
no athletes in this age group exhibited a pathological myocardial substrate at CE-CMR. This confirms 
previous studies results suggesting that aging is associated with an increasing PVBs burden that does 
not necessarily correlate with an underlying cardiac disease106-108.  
 The findings of this study, that for the first time included unselected volunteers (and not only 
athletes that were referred for arrhythmias at preparticipation screening), did not confirm the 
perspective that the amount of sports activity influences the PVBs burden102-105. In fact, at 
multivariate analysis, neither the years of sports activity nor the number of hours of practice per 
week significantly correlated with the presence of >29 PVBs/day at 24-hours ambulatory ECG 
monitoring. Further supporting this hypothesis is the comparison between the present study and the 
recent study by Hingorani et al.109, who analyzed the 24-hours ambulatory ECG monitoring results of 
1273 healthy volunteers <65 year-old included in phase 1 drug studies and found that the prevalence 
of PVBs >50/day, >100/day, >1000/day or >2000/day was comparable to that of our athletes (Table 
16). Moreover, Hingorani et al. also found a higher prevalence and complexity of VA in volunteers 46-
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65 year-old compared with 18-45 year-old. However, it has to be recognized that the to conclude 
with certainty that exercise is not related to ectopy a much larger study would be required. 
  
Table 16 – Comparison between premature ventricular beats (PVBs) count in the present study and 
in the study by Hingorani et al.109 including healthy volunteers from the general population. 
 
Hingorani et al. 
N=1273 
General population 
Present study 
N=384 
Athletes 
P 
>0 PVB 551 (43.3%) 251 (57.3%) P<0.001 
>50 PVBs 150 (11.8%) 31 (8.1%) 0.06 
>100 PVBs 116 (9.1%) 23 (6.0%) 0.07 
>1000 PVBs 23 (1.8%) 8 (2.1%) 0.73 
>2000 PVBs 13 (1.0%) 4 (1.0%) 1.0 
  
Limitations of the studies 
 The three studies have some limitations that must be acknowledged. The main limitation of 
the first study (incidence and causes of juvenile OHCA) is that autopsy was not performed in 8 cases 
and, as a consequence, the distribution of causes of OHCA could not be precisely assessed. The 
second study (profile and outcome of athletes with VA and LGE at CE-CMR) observed a relatively 
small number of arrhythmic events during follow-up and, as a consequence, the power to detect 
associations was low. In particular, the small number of athletes with VA and junctional “spotty” LGE 
did not allow us to confidently conclude that this LGE pattern is associated with a benign outcome. 
The main limitation of the third study is that athletes were not consecutive but volunteers that were 
included only if they were considered eligible at preparticipation screening: hence, the prevalence 
and underlying substrate of VA in the general population of athletes cannot be reliably assessed. 
Although we did not find any athlete >35 year-old with LV LGE, VA may be related to coronary artery 
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disease that cannot be definitely rule out by a normal CE-CMR. However, none of our older athletes 
complained of symptoms suggestive of myocardial ischemia and all underwent maximal stress test 
within 1 year (required by the Italian Law as part of the preparticipation screening protocol in 
athletes >35 year-old) that resulted negative for ST-segment changes. Moreover, the conclusions are 
based on a relatively low number of athletes with arrhythmias and underlying ventricular scar and 
further studies are needed to confirm this findings. 
 
Clinical implications 
 Taken together the results of the first two studies suggest that the non-ischemic LV scar with 
a “stria” morphologic pattern and subepicardial/midmyocardial distribution is an emerging cause of 
malignant VA and SD in the young and athlete and cannot be simply dismissed as a benign sign of a 
healed remote inflammatory process. In fact, this condition may be found also in cardiomyopathies 
(particularly the left-dominant variant of ARVC) and may represent an arrhythmic substrate 
regardless of its origin. 
 The results of these two studies raise the question as to how to identify asymptomatic and 
apparently healthy athletes with at-risk LV scar. The finding of a ≈50% prevalence of ECG 
abnormalities, either T-wave inversion in the infero-lateral leads or low QRS voltages in limb leads, in 
our athletes with a “stria” LGE pattern suggests the possibility that the disease may be suspected by 
ECG screening in some cases. However, because of its peculiar non transmural distribution which 
spares the subendocardial wall layer, the presence of LV scar is easily missed by echocardiography. 
As a corollary, in athletes presenting with frequent PVBs or complex arrhythmias (particularly with a 
RBBB pattern), particularly if associated with T-wave inversion in the infero-lateral leads or low QRS 
voltages in the limb leads, should be prescribed a CE-CMR to exclude an underlying arrhythmogenic 
substrate. However, many athletes with VA are asymptomatic and preparticipation screening that is 
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based on history, physical examination and resting 12-leads ECG, may have a limited sensitivity to 
detect arrhythmias. Hence, we performed a prospective study in which we enrolled volunteers 
athletes that were already considered eligible according to current preparticipation screening and 
tested the utility of 12-leads ambulatory ECG monitoring as a first-line investigation and CE-CMR as a 
second-line investigation (reserved to athletes with “atypical PVBs” or repetitive arrhythmias) to 
detect concealed LV scar. We found that this protocol may be particularly advantageous in healthy 
young athlete who usually show a very low arrhythmic burden and that demonstrated an high 
prevalence of underlying LV-scar at CE-CMR when “uncommon” PVBs (especially if exercise-induced 
PVBs with a RBBB configuration) are recorded. Although implementation of the 12-leads ambulatory 
ECG monitoring as a screening tool needs further validation, the study results suggest that the 
decision to perform CE-CMR in a young athlete with PVBs should be based on arrhythmia 
morphology (suggesting the origin) rather than the number (as benign PVBs such as fascicular and 
right ventricular outflow tract arrhythmias can be very frequent). As a consequence, the ambulatory 
24-hours ECG monitor in an athlete should have 12-leads and the exam should include a training 
session, possibly of the same sport the athlete habitually performs.  
 The most appropriate management strategy of athletes with LV scar remains to be 
established. An isolated non-ischemic LV LGE is not listed by the current recommendations among 
the cardiac diseases at risk of SCD and requiring restriction or disqualification from competitive 
sports activity. Our findings indicate that, in the presence of a stria of LV LGE and VA, especially if 
worsened by exercise, athletes should prudentially refrain from practicing sports activity and physical 
exercise with high cardiovascular demand. Whether this should apply also to athletes with incidental 
finding of LGE in the absence of arrhythmias remains to be established. About the clinical 
management, by extrapolation from other arrhythmogenic disorders at risk of SD, ICD implantation is 
indicated in affected athletes who survived cardiac arrest due to ventricular fibrillation, experienced 
sustained ventricular tachycardia or had exercise-induced syncope. Successful mapping/catheter 
ablation of recurrent sustained ventricular tachycardia have been preliminary reported in patients 
DISCUSSION 
82 
 
with inferolateral scar using an epicardial approach because the reentry circuit is located in the outer 
layer of LV wall110. Prophylactic beta-blocker therapy seems to be justified on the basis of the 
exercise test inducibility VA in the majority of our cases. However, such a therapy may not confer 
complete protection against life-threatening VA as shown by the significant incidence of appropriate 
ICD intervention on fast ventricular tachycardia during follow-up observed in our study population 
despite beta blockers. Of note, because the scar may be inheritable, a cascade family screening and 
clinical follow-up is warranted. 
 Finally, the results of these studies can form the basis for a number of future research 
projects as well as collaborative work with bigger numbers and therefore more definitive conclusions 
particularly on the etiopathogenesis of the LV scar, strategies for early diagnosis and risk 
stratification of affected individuals. 
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